desipramine has been researched along with Depression in 340 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter." | 9.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Thirty outpatients between the ages of 60 and 85 with DSM-III Major Depression entered an 8 week randomized, double-blind comparison of desipramine and adinazolam mesylate, a triazolobenzodiazepine derivative." | 9.06 | A controlled trial of adinazolam versus desipramine in geriatric depression. ( Boyer, WF; Doroski, VS; Feighner, JP; Hendrickson, GG; Pambakian, RA, 1990) |
| " Desipramine is a typical tricyclic antidepressant, and can provide neuroprotection and counteract depression-like behaviors." | 7.85 | Desipramine rescues age-related phenotypes in depression-like rats induced by chronic mild stress. ( Chen, Y; Fu, Z; Huang, L; Ma, L; Shen, Q; Wang, Q; Wu, T; Xie, X, 2017) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 7.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| " The purpose of the present investigation was two-fold: to confirm the antidepressant-like effects of saredutant using a genetic animal model of depression, the Flinders Sensitive Line (FSL) rat, and to assess whether saredutant might synergize with desipramine to produce antidepressant-like effects at doses not seen with the individual compounds." | 7.76 | Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. ( Griebel, G; Naimoli, VM; Overstreet, DH, 2010) |
| "The purpose of this study was to examine the metabolites of lofepramine (LOF), namely desipramine (DMI), desmethyl desipramine (DDMI) and desmethyl lofepramine (DML) in the forced swim and olfactory bulbectomized (OB) rat models of depression." | 7.70 | An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression. ( Kelly, JP; Leonard, BE, 1999) |
| "The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity." | 7.69 | Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. ( Lang, A; Männistö, PT; Rauhala, P; Vasar, E, 1995) |
| "To test the hypothesis that a new potent and selective 5-HT2 receptor antagonist would be an excellent blocker of D,L-5-hydroxytryptophan (5-HTP)-induced response suppression in an animal model of depression, we administered LY53857 60 min prior to 5-HTP injections into rats working on an operant schedule for milk reinforcement." | 7.67 | Blockade of a 5-hydroxytryptophan-induced animal model of depression with a potent and selective 5-HT2 receptor antagonist (LY53857). ( Aprison, MH; Fuller, RW; Hingtgen, JN; Mason, NR, 1985) |
| "The response to imipramine (IMI) in children with depression has been shown to correlate with total levels of IMI plus its active metabolite desmethylimipramine (DMI)." | 7.67 | Targeting imipramine dose in children with depression. ( Perel, J; Rancurello, M; Sallee, F; Stiller, R, 1986) |
| "The role of the central histaminergic system in depression was studied by using swimming despair test in mice - a behavioural model of depression." | 7.67 | Role of central histaminergic mechanism in behavioural depression (swimming despair) in mice. ( Dhawan, KN; Gulati, A; Gupta, GP; Nath, C, 1988) |
| "Effects of lisuride, a central dopamine and serotonin agonist of the ergot type, in animal models of depression were investigated in comparison with those of desipramine, mianserin and rolipram." | 7.67 | [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants]. ( Ikoma, Y; Kimura, K; Kobayashi, S; Nakada, Y; Nakagawa, H; Nakamura, K; Yamaguchi, M, 1989) |
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 6.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| "Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressants." | 6.67 | Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. ( Dubner, R; Gracely, RH; Kishore-Kumar, R; Max, MB; Meister, B; Schafer, SC; Smoller, B, 1991) |
| "Depression has been related to relapsed drinking in alcoholics striving to maintain sobriety." | 6.67 | Desipramine treatment of alcoholism. ( Kocsis, JH; Mason, BJ, 1991) |
| "Desipramine treatment significantly reduced immobility in the tail suspension and forced swim tests, restored sociability in the three-chambered social approach task and reversed impairments in contextual fear conditioning in En2−/− mice." | 5.40 | Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice. ( Brielmaier, J; Crawley, JN; DiCicco-Bloom, E; Matteson, PG; Millonig, JH; Senerth, JM; Silverman, JL, 2014) |
| "Desipramine pretreatment reduced the time spent immobile in rats of the 2 alcohol-nonpreferring lines (i." | 5.30 | Comparison of rats selectively bred for high and low ethanol intake in a forced-swim-test model of depression: effects of desipramine. ( Froehlich, JC; Godfrey, CD; Li, TK; Murphy, JM; Stewart, RB, 1997) |
| "in seven male depressed patients with melancholia and five healthy male control subjects." | 5.27 | Patterns of melatonin rhythms in depression. ( Amsterdam, J; Brown, R; Caroff, S; Frazer, A; Kocsis, J; Stokes, P; Sweeney, J; Winokur, A, 1986) |
| "Twenty-six symptomatic subjects who met research diagnostic criteria for major affective disorder and were free of cardiovascular disease were treated for 3 wk with a fixed dosage schedule of desipramine (DMI) to a maximum of 200 mg/day." | 5.26 | Electrocardiogram changes and plasma desipramine levels during treatment of depression. ( Bielski, R; Bloom, V; Friedel, RO; Veith, RC, 1980) |
| " The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD)." | 5.10 | Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. ( Akman, D; Bangdiwala, SI; Blackman, CJ; Bradshaw, B; Dalton, CB; Diamant, NE; Drossman, DA; Duncan, S; Emmott, S; Frusciante, K; Hu, Y; Jia, H; Koch, GG; Le, T; Li, JZ; Meyer, K; Mikula, K; Morris, CB; Proffitt, V; Toner, BB; Whitehead, WE, 2003) |
| "Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter." | 5.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Forty-seven patients with definite rheumatoid arthritis (RA) were treated in a 32 week, double blind, crossover trial of amitriptyline, desipramine, trazodone, and placebo." | 5.06 | Antidepressant analgesia in rheumatoid arthritis. ( Atwood, C; Beck, NC; Brownlee-Duffeck, M; Elliott, TR; Frank, RG; Haut, AE; Kashani, JH; Kay, DR; Parker, JC; Smith, E, 1988) |
| "Thirty outpatients between the ages of 60 and 85 with DSM-III Major Depression entered an 8 week randomized, double-blind comparison of desipramine and adinazolam mesylate, a triazolobenzodiazepine derivative." | 5.06 | A controlled trial of adinazolam versus desipramine in geriatric depression. ( Boyer, WF; Doroski, VS; Feighner, JP; Hendrickson, GG; Pambakian, RA, 1990) |
| "The efficacy of desipramine for mild depression was tested in a double-blind, placebo-controlled study of outpatients with scores below 19 on the Hamilton Rating Scale for Depression (HAM-D)." | 5.05 | Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. ( Harrison, WM; Klein, DF; Liebowitz, MR; McGrath, PJ; Quitkin, FM; Stewart, JW, 1983) |
| "On the grounds of different pharmacological properties and possibly different clinical effects, two antidepressants, Anafranil (clomipramine) and Pertofran (desipramine) were compared in the management of depression in general practice." | 5.04 | A comparative trial of Anafranil, Pertofran and an Anafranil/Pertofran combination. ( Murphy, JE, 1977) |
| "The relationship between the antidepressive effect of imipramine and the plasma concentrations of imipramine and the active metabolite desipramine was studied in 24 patients suffering from endogenous depression." | 5.04 | Plasma levels and antidepressive effect of imipramine. ( Bech, P; Christiansen, J; Dencker, SJ; Gram, LF; Ibsen, I; Nagy, A; Petersen, GO; Reisby, N, 1976) |
| "Both desipramine and paroxetine show a trend towards efficacy in depression in MS the short term, but both treatments were associated with adverse effects, with significantly more patients treated with paroxetine suffering from nausea or headache." | 4.87 | Pharmacologic treatment of depression in multiple sclerosis. ( De Keyser, J; Glazenborg, A; Koch, MW; Mostert, J; Uyttenboogaart, M, 2011) |
| " In a 14-week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher." | 4.87 | Treatment of depressive symptoms in Parkinson's disease. ( Barone, P, 2011) |
| " Desipramine is a typical tricyclic antidepressant, and can provide neuroprotection and counteract depression-like behaviors." | 3.85 | Desipramine rescues age-related phenotypes in depression-like rats induced by chronic mild stress. ( Chen, Y; Fu, Z; Huang, L; Ma, L; Shen, Q; Wang, Q; Wu, T; Xie, X, 2017) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 3.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "We have investigated the effect of istradefylline on depression-like behaviors using the rat learned helplessness (LH) model." | 3.80 | Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. ( Jenner, P; Kanda, T; Kobayashi, M; Mori, A; Ohta, T; Shiozaki, S; Yamada, K, 2014) |
| " The purpose of the present investigation was two-fold: to confirm the antidepressant-like effects of saredutant using a genetic animal model of depression, the Flinders Sensitive Line (FSL) rat, and to assess whether saredutant might synergize with desipramine to produce antidepressant-like effects at doses not seen with the individual compounds." | 3.76 | Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. ( Griebel, G; Naimoli, VM; Overstreet, DH, 2010) |
| "Nicotine withdrawal is characterized by depression-like symptomatology that may be mediated by dysregulations in norepinephrine transmission." | 3.74 | The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. ( Markou, A; Paterson, NE; Semenova, S, 2008) |
| "The objective of this study was to investigate whether bilateral dopamine depletion within the medial prefrontal cortex affects depression state, as well as the antidepressant efficacy of desipramine, in the forced swimming test." | 3.70 | Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. ( Espejo, EF; Miñano, FJ, 1999) |
| "The purpose of this study was to examine the metabolites of lofepramine (LOF), namely desipramine (DMI), desmethyl desipramine (DDMI) and desmethyl lofepramine (DML) in the forced swim and olfactory bulbectomized (OB) rat models of depression." | 3.70 | An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression. ( Kelly, JP; Leonard, BE, 1999) |
| "The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity." | 3.69 | Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. ( Lang, A; Männistö, PT; Rauhala, P; Vasar, E, 1995) |
| "We have previously found that repeated phencyclidine (PCP) treatment enhances the immobility induced by forced swimming and suggested that this behavioral change could be used as a model of the negative symptoms, particularly depression, of schizophrenia." | 3.69 | Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. ( Furukawa, H; Mamiya, T; Nabeshima, T; Noda, Y, 1997) |
| "The influence of alpha 2-adrenoceptor blockade on the activity of desipramine in an experimental model of depression was studied by using idazoxan and 1-(pyrimidinyl)piperazine (1-PP)." | 3.68 | Alpha 2-adrenoceptor blockade prevents the effect of desipramine in the forced swimming test. ( Cervo, L; Grignaschi, G; Samanin, R, 1990) |
| "Effects of lisuride, a central dopamine and serotonin agonist of the ergot type, in animal models of depression were investigated in comparison with those of desipramine, mianserin and rolipram." | 3.67 | [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants]. ( Ikoma, Y; Kimura, K; Kobayashi, S; Nakada, Y; Nakagawa, H; Nakamura, K; Yamaguchi, M, 1989) |
| " The degree of anorexia and plasma corticosterone elevation in response to the stress was measured." | 3.67 | The effect of acute and chronic administration of desmethylimipramine on responses to stress in rats. ( Platt, JE; Stone, EA; Trullas, R, 1984) |
| "The role of the central histaminergic system in depression was studied by using swimming despair test in mice - a behavioural model of depression." | 3.67 | Role of central histaminergic mechanism in behavioural depression (swimming despair) in mice. ( Dhawan, KN; Gulati, A; Gupta, GP; Nath, C, 1988) |
| "The response to imipramine (IMI) in children with depression has been shown to correlate with total levels of IMI plus its active metabolite desmethylimipramine (DMI)." | 3.67 | Targeting imipramine dose in children with depression. ( Perel, J; Rancurello, M; Sallee, F; Stiller, R, 1986) |
| " We present a case of significant behavioral side effects in a young woman secondary to elevated plasma levels of imipramine and desipramine, masquerading as an agitated psychotic depression." | 3.67 | Profound behavioral toxicity due to tricyclic antidepressants. ( Grunhaus, L; Meador-Woodruff, JH, 1986) |
| "To test the hypothesis that a new potent and selective 5-HT2 receptor antagonist would be an excellent blocker of D,L-5-hydroxytryptophan (5-HTP)-induced response suppression in an animal model of depression, we administered LY53857 60 min prior to 5-HTP injections into rats working on an operant schedule for milk reinforcement." | 3.67 | Blockade of a 5-hydroxytryptophan-induced animal model of depression with a potent and selective 5-HT2 receptor antagonist (LY53857). ( Aprison, MH; Fuller, RW; Hingtgen, JN; Mason, NR, 1985) |
| "The effects of ECT, amitriptyline, clomipramine, maprotiline and desipramine on the course of endogenous depression were compared in 105 patients using repeated self-administered mood questionnaires as the outcome measure." | 3.66 | Effects of somatic treatments on mood in endogenous depression. ( Albert, W; Klicpera, C; Strian, F, 1979) |
| "The electrocardiographic effects of imipramine hydrochloride at therapeutic plasma concentrations were determined in 44 depressed patients during a 6-week clinical outcome study of depression." | 3.66 | The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. ( Bigger, JT; Giardina, EG; Glassman, AH; Kantor, SJ; Perel, JM, 1979) |
| "Ten patients with psychotic depression were assessed on a battery of clinical, EEG, psychological, and biochemical measures during treatment with imipramine (150 mg/day)." | 3.65 | The electroencephalographic and psychological effects of imipramine in depressed inpatients. ( Bhanji, S; Lader, M, 1977) |
| " In latent of manifest glaucoma (7 patients) Clomipramine increased the tonography in 1 case, whereas Amitriptyline and Noxiptiline reduced it in 4 cases." | 3.65 | [Psychotropic drugs and glaucoma (author's transl)]. ( Andrée, G; Meiser, H; Schmitt, W, 1976) |
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 2.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| " Subjects were then treated with DMI, titrated to an average DMI dosage of 3 mg/kg, and underwent repeated exercise testing." | 2.69 | Cardiovascular effects of desipramine in children and adults during exercise testing. ( Bigger, JT; Bilich, K; Giardina, EG; Greenhill, LL; Sloan, RP; Walsh, BT; Waslick, BD, 1999) |
| "Paroxetine was given as a fixed dose of 40 mg/day, while the dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 400-600 nM." | 2.67 | The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. ( Brøsen, K; Eshøj, O; Gram, LF; Mogensen, EF; Sindrup, SH, 1990) |
| "Depression has been related to relapsed drinking in alcoholics striving to maintain sobriety." | 2.67 | Desipramine treatment of alcoholism. ( Kocsis, JH; Mason, BJ, 1991) |
| "Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressants." | 2.67 | Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. ( Dubner, R; Gracely, RH; Kishore-Kumar, R; Max, MB; Meister, B; Schafer, SC; Smoller, B, 1991) |
| "Treatment with imipramine inhibited metabolism of both sparteine and debrisoquine (MR values about doubled), but did not affect the interpatient correlations." | 2.66 | Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. ( Bech, P; Bertilsson, L; Brøsen, K; Gram, LF; Klysner, R; Otton, SV, 1986) |
| "A multicentre comparative clinical evaluation of lofepramine, an imipramine analogue, and imipramine has been made with double-blind technique and fixed dosage (lofepramine 70 mg t." | 2.64 | Comparative clinical evaluation of lofepramine and imipramine. Pharmacological aspects. ( Borg, S; d'Elia, G; Forshell, GP; Lundin, G; Raotma, H; Román, G; Siwers, B, 1977) |
| " These include biological factors, such as strain, age, body weight, gender and individual differences between animals; influence of preconditioning before the FST: handling, social isolation or enriched environment, food manipulations, various kinds of stress, endocrine manipulations and surgery; schedule and routes of treatment, dosage and type of the drugs as well as experimental design and laboratory environmental effects." | 2.49 | Factors influencing behavior in the forced swim test. ( Bogdanova, OV; D'Anci, KE; Kanekar, S; Renshaw, PF, 2013) |
| " With chronic administration each of the antidepressants produced effects which could potentially interfere with CRF function in the LC." | 2.38 | Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. ( Curtis, AL; Valentino, RJ, 1991) |
| " Neurochemical studies show that both lofepramine and its metabolite are potent noradrenaline uptake inhibitors in vitro and evidence is presented to suggest that lofepramine may release this amine following chronic administration in vivo; both drugs slightly increase serotonin turnover under these conditions and down-regulate cortical beta-adrenoceptor function." | 2.37 | A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. ( Leonard, BE, 1987) |
| "Depression is a major health problem for which most patients are not effectively treated." | 1.56 | Effect of concurrent organic cation transporter blockade on norepinephrine clearance inhibiting- and antidepressant-like actions of desipramine and venlafaxine. ( Bowman, MA; Daws, LC; Horton, RE; Koek, W; Mitchell, NC; Owens, WA, 2020) |
| "Buprenorphine (BPN) has been shown to rapidly improve mood in treatment-resistant depressed patients in small clinical studies." | 1.42 | Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. ( Falcon, E; Hill-Smith, TE; Lucki, I; Maier, K; Robinson, SA, 2015) |
| "Desipramine treatment significantly reduced immobility in the tail suspension and forced swim tests, restored sociability in the three-chambered social approach task and reversed impairments in contextual fear conditioning in En2−/− mice." | 1.40 | Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice. ( Brielmaier, J; Crawley, JN; DiCicco-Bloom, E; Matteson, PG; Millonig, JH; Senerth, JM; Silverman, JL, 2014) |
| "CD-1 mice were dosed with Bacille Calmette-Guérin (BCG) and measures of body weight, locomotor activity, and immobility in the tail suspension test (TST) were made." | 1.39 | A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants. ( Clark, JA; Klee, N; Nizami, M; Platt, B; Schulenberg, J, 2013) |
| "Depression is associated with medical comorbidities, particularly cardiovascular disease." | 1.38 | Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor. ( Bhatnagar, S; Grigoriadis, D; McFadden, KV; Valentino, RJ; Wood, SK, 2012) |
| "Desipramine (DMI) is an antidepressant classically characterized as an inhibitor of norepinephrine reuptake." | 1.37 | The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. ( Chen, Y; Cottingham, C; Jiao, K; Wang, Q, 2011) |
| "The responses of olfactory bulbectomized (OBX) rats to antidepressant treatment are similar to those of depressed patients since chronic administration of an antidepressant reverses OBX-induced behavioral and physiological changes." | 1.35 | Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. ( Hirose, N; Kamei, J; Murasawa, H; Nakatani, A; Saitoh, A; Takahashi, K; Tatsumi, Y; Yamada, M; Yamaguchi, K, 2008) |
| " This study investigated the pharmacokinetic and pharmacological interactions between imipramine and sodium alginate in rats." | 1.35 | Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats. ( Aimoto, T; Araki, H; Imai, K; Inoue, N; Suemaru, K; Watanabe, S, 2008) |
| "Treatment with desipramine (20mg/kg, i." | 1.35 | Increased water temperature renders single-housed C57BL/6J mice susceptible to antidepressant treatment in the forced swim test. ( Bächli, H; Habersetzer, U; Steiner, MA; Wotjak, CT, 2008) |
| " The latter effect could be mimicked in C57BL/6N mice by acute, subchronic, and chronic administration of the selective CB1 antagonist SR141716." | 1.35 | Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. ( Holsboer, F; Lutz, B; Marsicano, G; Nestler, EJ; Steiner, MA; Wotjak, CT, 2008) |
| "Desipramine pretreatment reduced the time spent immobile in rats of the 2 alcohol-nonpreferring lines (i." | 1.30 | Comparison of rats selectively bred for high and low ethanol intake in a forced-swim-test model of depression: effects of desipramine. ( Froehlich, JC; Godfrey, CD; Li, TK; Murphy, JM; Stewart, RB, 1997) |
| "Because depression is often associated with stress, it has been hypothesized that antidepressants may influence stress-related adaptive responses in the brain." | 1.28 | Combined effects of desipramine and stress on monoamine turnover in rat brain. ( Naitoh, H; Nomura, S, 1990) |
| " A relationship between age and kinetic parameters such as area under the curve, elimination phase constant, half-life and total body clearance was observed." | 1.28 | Imipramine pharmacokinetics in depressed geriatric patients. ( Baraldo, M; Benetello, P; Furlanut, M; Zara, G, 1990) |
| "in seven male depressed patients with melancholia and five healthy male control subjects." | 1.27 | Patterns of melatonin rhythms in depression. ( Amsterdam, J; Brown, R; Caroff, S; Frazer, A; Kocsis, J; Stokes, P; Sweeney, J; Winokur, A, 1986) |
| "In imipramine-treated patients this finding was associated with a decreased rate of drug elimination from plasma." | 1.26 | Relationship between age and tricyclic antidepressant plasma levels. ( Cooper, TB; Friedman, MJ; Green, R; Ives, JO; Nies, A; Ravaris, CL; Robinson, DS, 1977) |
| " Plasma levels of the tricyclics were relatively stable on both dosage schedules due to the long plasma half-lives of these drugs." | 1.26 | Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time. ( Biggs, JT; Meyer, DA; Preskorn, SH; Rosen, SH; Ziegler, VE, 1978) |
| " Knowledge of the drug dose-response curve and its levels in blood may enable the physician to convert a patient from a "nonresponder" into a "responder." | 1.26 | High dose desipramine, plasma drug levels and clinical response. ( Amsterdam, J; Brunswick, DJ; Mendels, J, 1979) |
| "Tricyclic antidepressant plasma levels were measured in patients and healthy subjects after a single dise of desmethylimipramine (DMI) or imipramine (IMI) and after chronic dosing to steady states." | 1.26 | Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data. ( Amsterdam, JD; Brunswick, DJ; Mendels, J; Stern, SL, 1979) |
| " An inverse correlation between plasma levels of DMI and plasma levels of melatonin-like immunoreactivity was found in the group of clinical responders to the chronic administration of the drug." | 1.26 | An inverse correlation between serum levels of desmethylimipramine and melatonin-like immunoreactivity in DMI-responsive depressives. ( Halbreich, U; Klein, DF; Quitkin, FM; Stewart, J; Weinberg, U; Weitzman, ED, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 202 (59.41) | 18.7374 |
| 1990's | 42 (12.35) | 18.2507 |
| 2000's | 57 (16.76) | 29.6817 |
| 2010's | 34 (10.00) | 24.3611 |
| 2020's | 5 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Li, J | 2 |
| Huang, Y | 2 |
| Gong, Q | 1 |
| Fu, Y | 1 |
| Xu, Y | 1 |
| Huang, J | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Mao, F | 1 |
| Zhu, J | 1 |
| Wang, H | 2 |
| Zhang, H | 1 |
| Spulber, S | 2 |
| Conti, M | 2 |
| Elberling, F | 1 |
| Raciti, M | 2 |
| Borroto-Escuela, DO | 1 |
| Fuxe, K | 1 |
| Ceccatelli, S | 2 |
| Bowman, MA | 1 |
| Mitchell, NC | 1 |
| Owens, WA | 1 |
| Horton, RE | 1 |
| Koek, W | 2 |
| Daws, LC | 2 |
| Lamanna, J | 1 |
| Isotti, F | 1 |
| Ferro, M | 1 |
| Racchetti, G | 1 |
| Anchora, L | 1 |
| Rucco, D | 1 |
| Malgaroli, A | 1 |
| Ait Chait, Y | 1 |
| Mottawea, W | 1 |
| Tompkins, TA | 1 |
| Hammami, R | 1 |
| Chmielarz, P | 1 |
| Kuśmierczyk, J | 1 |
| Rafa-Zabłocka, K | 1 |
| Chorązka, K | 1 |
| Kowalska, M | 1 |
| Satała, G | 1 |
| Nalepa, I | 1 |
| Benham, RS | 1 |
| Hewage, NB | 1 |
| Suckow, RF | 3 |
| Engin, E | 1 |
| Rudolph, U | 1 |
| Xie, X | 1 |
| Chen, Y | 2 |
| Wang, Q | 2 |
| Shen, Q | 1 |
| Ma, L | 1 |
| Huang, L | 1 |
| Wu, T | 1 |
| Fu, Z | 1 |
| Sandoval, TL | 1 |
| Stratinaki, M | 1 |
| Varidaki, A | 1 |
| Mitsi, V | 1 |
| Ghose, S | 1 |
| Magida, J | 1 |
| Dias, C | 1 |
| Russo, SJ | 1 |
| Vialou, V | 1 |
| Caldarone, BJ | 1 |
| Tamminga, CA | 1 |
| Nestler, EJ | 2 |
| Zachariou, V | 1 |
| Bogdanova, OV | 1 |
| Kanekar, S | 1 |
| D'Anci, KE | 1 |
| Renshaw, PF | 2 |
| Piras, G | 2 |
| Piludu, MA | 1 |
| Giorgi, O | 2 |
| Corda, MG | 2 |
| Wąsik, A | 1 |
| Możdżeń, E | 1 |
| Michaluk, J | 1 |
| Romańska, I | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Wrona, D | 1 |
| Listowska, M | 1 |
| Kubera, M | 1 |
| Glac, W | 1 |
| Grembecka, B | 1 |
| Plucińska, K | 1 |
| Majkutewicz, I | 1 |
| Podlacha, M | 1 |
| Yamada, K | 1 |
| Kobayashi, M | 1 |
| Shiozaki, S | 1 |
| Ohta, T | 1 |
| Mori, A | 1 |
| Jenner, P | 1 |
| Kanda, T | 1 |
| Brielmaier, J | 1 |
| Senerth, JM | 1 |
| Silverman, JL | 1 |
| Matteson, PG | 1 |
| Millonig, JH | 1 |
| DiCicco-Bloom, E | 1 |
| Crawley, JN | 2 |
| Falcon, E | 1 |
| Maier, K | 1 |
| Robinson, SA | 1 |
| Hill-Smith, TE | 1 |
| Lucki, I | 2 |
| Chang, CH | 1 |
| Chen, MC | 1 |
| Lu, J | 1 |
| Mokoena, ML | 1 |
| Harvey, BH | 1 |
| Viljoen, F | 1 |
| Ellis, SM | 1 |
| Brink, CB | 1 |
| Aoki, M | 1 |
| Watanabe, Y | 1 |
| Yoshimoto, K | 1 |
| Tsujimura, A | 1 |
| Yamamoto, T | 1 |
| Kanamura, N | 1 |
| Tanaka, M | 1 |
| Dallé, E | 1 |
| Daniels, WM | 1 |
| Mabandla, MV | 1 |
| Hibicke, M | 1 |
| Graham, MA | 1 |
| Hayslett, RL | 1 |
| Lu, X | 1 |
| Ross, B | 1 |
| Sanchez-Alavez, M | 1 |
| Zorrilla, EP | 1 |
| Bartfai, T | 1 |
| Stevenson, JR | 1 |
| Schroeder, JP | 1 |
| Nixon, K | 1 |
| Besheer, J | 1 |
| Crews, FT | 1 |
| Hodge, CW | 1 |
| Yalcin, I | 1 |
| Belzung, C | 1 |
| Surget, A | 1 |
| Mathieu, G | 1 |
| Denis, S | 1 |
| Lavialle, M | 1 |
| Vancassel, S | 1 |
| Boyce-Rustay, JM | 1 |
| Palachick, B | 1 |
| Hefner, K | 1 |
| Chen, YC | 1 |
| Karlsson, RM | 1 |
| Millstein, RA | 1 |
| Harvey-White, J | 1 |
| Holmes, A | 2 |
| Getachew, B | 1 |
| Hauser, SR | 1 |
| Taylor, RE | 1 |
| Tizabi, Y | 1 |
| Molina-Hernández, M | 2 |
| Téllez-Alcántara, NP | 1 |
| Pérez-García, J | 1 |
| Olivera-Lopez, JI | 1 |
| Jaramillo-Jaimes, MT | 1 |
| Sugimoto, Y | 1 |
| Kajiwara, Y | 1 |
| Hirano, K | 1 |
| Yamada, S | 1 |
| Tagawa, N | 1 |
| Kobayashi, Y | 1 |
| Hotta, Y | 1 |
| Yamada, J | 1 |
| Stone, EA | 6 |
| Lin, Y | 5 |
| Quartermain, D | 3 |
| Aksoz, E | 1 |
| Aksoz, T | 1 |
| Bilge, SS | 1 |
| Ilkaya, F | 1 |
| Celik, S | 1 |
| Diren, HB | 1 |
| Nahas, Z | 1 |
| Jiang, Y | 1 |
| Zeidan, YH | 1 |
| Bielawska, A | 1 |
| Szulc, Z | 1 |
| Devane, L | 1 |
| Kalivas, P | 1 |
| Hannun, YA | 1 |
| Zhang, HT | 1 |
| Whisler, LR | 1 |
| Xiang, Y | 1 |
| O'Donnell, JM | 1 |
| Hajszan, T | 1 |
| Dow, A | 1 |
| Warner-Schmidt, JL | 1 |
| Szigeti-Buck, K | 1 |
| Sallam, NL | 1 |
| Parducz, A | 1 |
| Leranth, C | 1 |
| Duman, RS | 2 |
| Berrocoso, E | 1 |
| Mico, JA | 1 |
| Gundersen, BB | 1 |
| Blendy, JA | 1 |
| Schenk, PW | 1 |
| van Vliet, M | 1 |
| Mathot, RA | 1 |
| van Gelder, T | 1 |
| Vulto, AG | 1 |
| van Fessem, MA | 1 |
| Verploegh-Van Rij, S | 1 |
| Lindemans, J | 1 |
| Bruijn, JA | 1 |
| van Schaik, RH | 1 |
| Sacharczuk, M | 1 |
| Juszczak, G | 1 |
| Swiergiel, AH | 1 |
| Jaszczak, K | 1 |
| Lipkowski, AW | 1 |
| Sadowski, B | 1 |
| Thangathurai, D | 1 |
| Roby, J | 1 |
| Roffey, P | 1 |
| Sarfraz, Y | 2 |
| Overstreet, DH | 10 |
| Naimoli, VM | 1 |
| Griebel, G | 2 |
| Drugan, RC | 1 |
| Macomber, H | 1 |
| Warner, TA | 1 |
| Barone, P | 1 |
| Koch, MW | 1 |
| Glazenborg, A | 1 |
| Uyttenboogaart, M | 1 |
| Mostert, J | 1 |
| De Keyser, J | 1 |
| Sato, H | 1 |
| Skelin, I | 1 |
| Diksic, M | 1 |
| Cottingham, C | 1 |
| Jiao, K | 1 |
| Socała, K | 1 |
| Nieoczym, D | 1 |
| Wyska, E | 1 |
| Poleszak, E | 1 |
| Wlaź, P | 1 |
| Wood, SK | 1 |
| McFadden, KV | 1 |
| Grigoriadis, D | 1 |
| Bhatnagar, S | 1 |
| Valentino, RJ | 2 |
| O'Connor, RM | 1 |
| Pusceddu, MM | 1 |
| O'Leary, OF | 2 |
| Savignac, HM | 1 |
| Bravo, JA | 1 |
| El Yacoubi, M | 1 |
| Vaugeois, JM | 2 |
| Dinan, TG | 1 |
| Cryan, JF | 2 |
| LeGates, TA | 1 |
| Altimus, CM | 1 |
| Lee, HK | 1 |
| Yang, S | 1 |
| Zhao, H | 1 |
| Kirkwood, A | 1 |
| Weber, ET | 1 |
| Hattar, S | 1 |
| Platt, B | 1 |
| Schulenberg, J | 1 |
| Klee, N | 1 |
| Nizami, M | 1 |
| Clark, JA | 1 |
| Urani, A | 1 |
| Romieu, P | 1 |
| Portales-Casamar, E | 1 |
| Roman, FJ | 1 |
| Maurice, T | 1 |
| Alcaro, A | 1 |
| Cabib, S | 1 |
| Ventura, R | 1 |
| Puglisi-Allegra, S | 1 |
| Rénéric, JP | 1 |
| Bouvard, M | 1 |
| Stinus, L | 1 |
| Drossman, DA | 1 |
| Toner, BB | 1 |
| Whitehead, WE | 1 |
| Diamant, NE | 1 |
| Dalton, CB | 1 |
| Duncan, S | 1 |
| Emmott, S | 1 |
| Proffitt, V | 1 |
| Akman, D | 1 |
| Frusciante, K | 1 |
| Le, T | 1 |
| Meyer, K | 1 |
| Bradshaw, B | 1 |
| Mikula, K | 1 |
| Morris, CB | 1 |
| Blackman, CJ | 1 |
| Hu, Y | 1 |
| Jia, H | 1 |
| Li, JZ | 1 |
| Koch, GG | 1 |
| Bangdiwala, SI | 1 |
| Ripoll, N | 1 |
| David, DJ | 1 |
| Dailly, E | 2 |
| Hascoët, M | 1 |
| Bourin, M | 2 |
| BAN, TA | 2 |
| LEHMANN, HE | 3 |
| FRAME, MC | 1 |
| POELDINGER, W | 6 |
| KRAKOWSKI, AJ | 2 |
| ROLLE, T | 1 |
| ALNAES, R | 3 |
| KRISTIANSEN, J | 2 |
| VOLTERRA, V | 1 |
| GUERMANI, M | 1 |
| SIEGLER, PE | 1 |
| SHIOSAKI, S | 1 |
| TAKASHIO, T | 1 |
| HOSAKA, K | 1 |
| ROSE, JT | 3 |
| WESTHEAD, TT | 2 |
| ENGELMEIER, MP | 1 |
| PALESTINE, ML | 1 |
| BARRINGER, TJ | 1 |
| HORDERN, A | 1 |
| LAPOLLA, A | 2 |
| POLLITT, J | 1 |
| WALDRON, J | 1 |
| BATES, TJ | 1 |
| LAMONT, ES | 1 |
| MANN, AM | 1 |
| OLTMAN, JE | 1 |
| FRIEDMAN, S | 1 |
| MacQueen, GM | 1 |
| Ramakrishnan, K | 1 |
| Ratnasingan, R | 1 |
| Chen, B | 1 |
| Young, LT | 1 |
| Rex, A | 1 |
| Schickert, R | 1 |
| Fink, H | 1 |
| Lopez-Rodriguez, F | 1 |
| Kim, J | 1 |
| Poland, RE | 1 |
| Hlavka, J | 1 |
| Feighner, JP | 2 |
| Nicolau, G | 1 |
| Freed, JS | 1 |
| Tatarczyńska, E | 1 |
| Kłodzińska, A | 1 |
| Stachowicz, K | 1 |
| Chojnacka-Wójcik, E | 1 |
| Jin, SH | 1 |
| Friedland, JC | 1 |
| Ouyang, M | 1 |
| Hirsch, BR | 1 |
| Page, ME | 1 |
| Dalvi, A | 1 |
| Thomas, SA | 1 |
| Flores, DL | 1 |
| Alvarado, I | 1 |
| Wong, ML | 1 |
| Licinio, J | 1 |
| Flockhart, D | 1 |
| Li, Q | 1 |
| Koenig, EA | 1 |
| Gold, E | 1 |
| Stephenson, D | 1 |
| Yang, RJ | 1 |
| Dreiling, J | 1 |
| Sullivan, T | 1 |
| Singewald, N | 1 |
| Sinner, C | 1 |
| Hetzenauer, A | 1 |
| Sartori, SB | 1 |
| Murck, H | 1 |
| Dremencov, E | 2 |
| Newman, ME | 2 |
| Kinor, N | 1 |
| Blatman-Jan, G | 1 |
| Schindler, CJ | 1 |
| Yadid, G | 5 |
| Friedman, A | 1 |
| Crown, H | 1 |
| Levy, D | 1 |
| Mintz, M | 1 |
| Carlezon, WA | 1 |
| Rohan, ML | 1 |
| Mague, SD | 1 |
| Meloni, EG | 1 |
| Parsegian, A | 1 |
| Cayetano, K | 1 |
| Tomasiewicz, HC | 1 |
| Rouse, ED | 1 |
| Cohen, BM | 1 |
| Martínez-Mota, L | 1 |
| López-Rubalcava, C | 1 |
| Rodríguez-Manzo, G | 1 |
| Deak, T | 1 |
| Bellamy, C | 1 |
| D'Agostino, LG | 1 |
| Rosanoff, M | 1 |
| McElderry, NK | 1 |
| Bordner, KA | 1 |
| Dow, AL | 1 |
| Russell, DS | 1 |
| Barden, N | 2 |
| Shink, E | 1 |
| Labbé, M | 1 |
| Vacher, R | 1 |
| Rochford, J | 1 |
| Mocaër, E | 1 |
| Chenu, F | 1 |
| Katz, MM | 1 |
| Bowden, CL | 1 |
| Berman, N | 1 |
| Frazer, A | 2 |
| Lehmann, ML | 1 |
| Pineda, MR | 1 |
| Russell, SC | 1 |
| Bächli, H | 1 |
| Steiner, MA | 2 |
| Habersetzer, U | 1 |
| Wotjak, CT | 2 |
| Marsicano, G | 1 |
| Holsboer, F | 1 |
| Lutz, B | 1 |
| Devos, D | 1 |
| Dujardin, K | 1 |
| Poirot, I | 1 |
| Moreau, C | 1 |
| Cottencin, O | 1 |
| Thomas, P | 1 |
| Destée, A | 1 |
| Bordet, R | 1 |
| Defebvre, L | 1 |
| Gonzalez, MM | 1 |
| Aston-Jones, G | 1 |
| Saitoh, A | 1 |
| Yamada, M | 2 |
| Takahashi, K | 1 |
| Yamaguchi, K | 1 |
| Murasawa, H | 1 |
| Nakatani, A | 1 |
| Tatsumi, Y | 1 |
| Hirose, N | 1 |
| Kamei, J | 1 |
| Paterson, NE | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Watanabe, S | 1 |
| Suemaru, K | 1 |
| Inoue, N | 1 |
| Imai, K | 1 |
| Aimoto, T | 1 |
| Araki, H | 1 |
| Popik, P | 1 |
| Kos, T | 1 |
| Sowa-Kućma, M | 1 |
| Nowak, G | 1 |
| Kahr, H | 1 |
| Battegay, R | 2 |
| Pöldinger, W | 1 |
| Angst, J | 2 |
| Cornu, F | 1 |
| Dick, P | 2 |
| Heimann, H | 1 |
| Bohard, F | 1 |
| Le Borgne, Y | 1 |
| Guennoc, A | 1 |
| Klein, H | 1 |
| Masanes, P | 1 |
| Ropert, R | 1 |
| Sivadon, P | 1 |
| Brown, WA | 1 |
| Haier, RJ | 2 |
| Qualls, CB | 1 |
| Thompson, C | 3 |
| Checkley, SA | 3 |
| Corn, T | 2 |
| Franey, C | 3 |
| Arendt, J | 3 |
| Mendlewicz, J | 2 |
| Stewart, JW | 2 |
| Quitkin, FM | 2 |
| Liebowitz, MR | 1 |
| McGrath, PJ | 1 |
| Harrison, WM | 1 |
| Klein, DF | 2 |
| Trullas, R | 1 |
| Platt, JE | 1 |
| Costa, D | 1 |
| Predescu, V | 1 |
| Vişan-Ionescu, I | 1 |
| Ciurezu, T | 1 |
| Bertilsson, L | 2 |
| Aberg-Wistedt, A | 1 |
| Halbreich, U | 1 |
| Weinberg, U | 1 |
| Stewart, J | 1 |
| Weitzman, ED | 1 |
| Amsterdam, J | 3 |
| Brunswick, D | 2 |
| Mendels, J | 6 |
| Marshall, JB | 1 |
| Forker, AD | 1 |
| Kitanaka, I | 1 |
| Ross, RJ | 1 |
| Cutler, NR | 1 |
| Zavadil, AP | 1 |
| Potter, WZ | 2 |
| Fibiger, HC | 1 |
| Phillips, AG | 1 |
| Hrdina, PD | 2 |
| Lapierre, YD | 1 |
| Rudorfer, MV | 1 |
| Young, RC | 1 |
| Lindsay, PG | 1 |
| Wyckoff, M | 1 |
| Veith, RC | 2 |
| Friedel, RO | 2 |
| Bloom, V | 2 |
| Bielski, R | 1 |
| Chinn, DM | 1 |
| Jennison, TA | 1 |
| Crouch, DJ | 1 |
| Peat, MA | 1 |
| Thatcher, GW | 1 |
| Quitkin, F | 1 |
| Fyer, A | 1 |
| Cannizzaro, C | 2 |
| Cannizzaro, E | 1 |
| Gagliano, M | 2 |
| Mineo, A | 1 |
| Sabatino, M | 1 |
| Cannizzaro, G | 2 |
| Männistö, PT | 1 |
| Lang, A | 1 |
| Rauhala, P | 1 |
| Vasar, E | 1 |
| Spina, E | 1 |
| Avenoso, A | 1 |
| Campo, GM | 1 |
| Caputi, AP | 1 |
| Perucca, E | 1 |
| Dwyer, KD | 1 |
| Roy, EJ | 1 |
| Bushell, I | 1 |
| Newton, W | 1 |
| Komori, T | 1 |
| Fujiwara, R | 1 |
| Tanida, M | 1 |
| Nomura, J | 1 |
| Noda, Y | 1 |
| Mamiya, T | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 1 |
| Godfrey, CD | 1 |
| Froehlich, JC | 1 |
| Stewart, RB | 1 |
| Li, TK | 1 |
| Murphy, JM | 1 |
| Zangen, A | 3 |
| Connor, TJ | 2 |
| Kelly, JP | 3 |
| Leonard, BE | 4 |
| Passera, G | 1 |
| Zuccaro, F | 1 |
| Costentin, J | 1 |
| Pucilowski, O | 2 |
| Retton, MC | 1 |
| Delagrange, P | 1 |
| Guardiola-Lemaitre, B | 1 |
| Levitt, AJ | 1 |
| Wesson, VA | 1 |
| Joffe, RT | 1 |
| Béïque, JC | 1 |
| de Montigny, C | 1 |
| Blier, P | 1 |
| Debonnel, G | 1 |
| Wang, Y | 1 |
| Freund, RK | 1 |
| Palmer, MR | 1 |
| Waslick, BD | 1 |
| Walsh, BT | 1 |
| Greenhill, LL | 1 |
| Giardina, EG | 2 |
| Sloan, RP | 1 |
| Bigger, JT | 2 |
| Bilich, K | 1 |
| Espejo, EF | 1 |
| Miñano, FJ | 1 |
| Harkin, A | 1 |
| Téllez-Alcántara, P | 2 |
| Tyra, JM | 1 |
| Greenawald, MH | 1 |
| Srivastava, SK | 1 |
| Nath, C | 2 |
| Consogno, E | 1 |
| Racagni, G | 1 |
| Popoli, M | 1 |
| Nakash, R | 1 |
| Pallis, E | 1 |
| Thermos, K | 1 |
| Spyraki, C | 1 |
| Molina, M | 1 |
| Contreras, CM | 1 |
| Sammut, S | 1 |
| Bethus, I | 1 |
| Goodall, G | 1 |
| Muscat, R | 2 |
| Adolphe, AB | 1 |
| Dorsey, ER | 1 |
| Napoliello, MJ | 1 |
| Maas, JW | 5 |
| Hollister, LE | 2 |
| Brunswick, DJ | 2 |
| von Kulmiz, P | 1 |
| Stretch, R | 1 |
| Siwers, B | 2 |
| Borg, S | 1 |
| d'Elia, G | 1 |
| Lundin, G | 1 |
| Forshell, GP | 1 |
| Raotma, H | 1 |
| Román, G | 1 |
| Schless, AP | 1 |
| Murphy, JE | 1 |
| De León, O | 1 |
| Kravcio, JT | 1 |
| Sánchez, C | 1 |
| Burgess, CD | 1 |
| Turner, P | 2 |
| Wadsworth, J | 1 |
| Khalid, R | 2 |
| Amin, MM | 2 |
| Cooper, R | 1 |
| Linnoila, M | 1 |
| Dorrity, F | 1 |
| Jobson, K | 1 |
| Kühne, GE | 2 |
| Grünes, JU | 1 |
| Knorr, W | 2 |
| Perina, L | 2 |
| Richter, H | 2 |
| Rommel, U | 1 |
| Sorger, R | 2 |
| Stöck, H | 2 |
| Waldow, N | 2 |
| Muscettola, G | 1 |
| Goodwin, FK | 1 |
| Claeys, MM | 1 |
| Markey, SP | 1 |
| Bielski, RJ | 1 |
| Amsterdam, JD | 1 |
| Stern, SL | 1 |
| Garbutt, J | 1 |
| Malekpour, B | 1 |
| Jonnalagadda, MR | 1 |
| Jolliff, L | 1 |
| Podolak, R | 1 |
| Wilson, I | 1 |
| Prange, A | 1 |
| Glassman, AH | 5 |
| Perel, JM | 9 |
| Kantor, SJ | 3 |
| Klicpera, C | 1 |
| Albert, W | 1 |
| Strian, F | 1 |
| Puig-Antich, J | 1 |
| Lupatkin, W | 1 |
| Chambers, WJ | 1 |
| Shea, C | 1 |
| Tabrizi, MA | 1 |
| Stiller, RL | 2 |
| Orsulak, PJ | 2 |
| Schildkraut, JJ | 3 |
| Appelbaum, PS | 1 |
| Vasile, RG | 1 |
| Nagy, A | 2 |
| Hansen, T | 1 |
| Risch, SC | 1 |
| Huey, LY | 1 |
| Janowsky, DS | 1 |
| Bhanji, S | 1 |
| Lader, M | 1 |
| Ziegler, VE | 1 |
| Biggs, JT | 1 |
| Rosen, SH | 1 |
| Meyer, DA | 1 |
| Preskorn, SH | 1 |
| Gram, LF | 3 |
| Reisby, N | 1 |
| Ibsen, I | 1 |
| Dencker, SJ | 1 |
| Bech, P | 2 |
| Petersen, GO | 1 |
| Christiansen, J | 1 |
| Piccione, M | 1 |
| Decina, P | 1 |
| Dionisio, A | 1 |
| Agnoli, A | 1 |
| Acébal, E | 1 |
| Subirá, S | 1 |
| Spatz, J | 1 |
| Faleni, R | 1 |
| Merzbacher, B | 1 |
| Gales, A | 1 |
| Moizeszowicz, J | 1 |
| Rommel, B | 1 |
| Fabiano, B | 1 |
| Blosfeld, G | 1 |
| Shostak, M | 2 |
| Fleiss, JL | 1 |
| Nies, A | 1 |
| Robinson, DS | 1 |
| Friedman, MJ | 1 |
| Green, R | 1 |
| Cooper, TB | 2 |
| Ravaris, CL | 1 |
| Ives, JO | 1 |
| Shaw, DM | 3 |
| Sathananthan, GL | 1 |
| Gershon, S | 1 |
| Almeida, M | 1 |
| Spector, N | 1 |
| Spector, S | 1 |
| Andrée, G | 1 |
| Schmitt, W | 2 |
| Meiser, H | 1 |
| Hurwic, MJ | 1 |
| Kanzler, MB | 1 |
| Woodward, JA | 1 |
| Henry, BW | 1 |
| Overall, JE | 2 |
| Belvedere, G | 2 |
| Burti, L | 1 |
| Frigerio, A | 2 |
| Pantarotto, C | 1 |
| Macsweeney, DA | 2 |
| Hewland, R | 1 |
| Johnson, AL | 2 |
| Flugy, A | 1 |
| Novara, V | 1 |
| Pepin, MC | 1 |
| Pothier, F | 1 |
| Max, MB | 2 |
| Lynch, SA | 1 |
| Muir, J | 1 |
| Shoaf, SE | 1 |
| Smoller, B | 2 |
| Dubner, R | 2 |
| Schiller, GD | 1 |
| Wienicke, C | 1 |
| Ziedonis, DM | 1 |
| Kosten, TR | 1 |
| Curtis, AL | 1 |
| Kishore-Kumar, R | 1 |
| Schafer, SC | 1 |
| Meister, B | 1 |
| Gracely, RH | 1 |
| Mason, BJ | 1 |
| Kocsis, JH | 1 |
| Cervo, L | 3 |
| Grignaschi, G | 3 |
| Samanin, R | 3 |
| Drago, F | 1 |
| Pulvirenti, L | 1 |
| Spadaro, F | 1 |
| Pennisi, G | 1 |
| Sindrup, SH | 1 |
| Brøsen, K | 2 |
| Eshøj, O | 1 |
| Mogensen, EF | 1 |
| Benetello, P | 1 |
| Furlanut, M | 1 |
| Zara, G | 1 |
| Baraldo, M | 1 |
| Lack, SJ | 1 |
| Baldwin, DS | 1 |
| Montgomery, SA | 1 |
| Boyer, WF | 1 |
| Hendrickson, GG | 1 |
| Pambakian, RA | 1 |
| Doroski, VS | 1 |
| Naitoh, H | 1 |
| Nomura, S | 1 |
| Nowakowska, E | 1 |
| Reist, C | 1 |
| Kauffmann, CD | 1 |
| Sangdahl, C | 1 |
| DeMet, EM | 1 |
| Chicz-DeMet, A | 1 |
| Nelson, JN | 1 |
| Bernardi, M | 1 |
| Vergoni, AV | 1 |
| Sandrini, M | 1 |
| Tagliavini, S | 1 |
| Bertolini, A | 1 |
| Nakamura, K | 1 |
| Ikoma, Y | 1 |
| Kimura, K | 1 |
| Nakada, Y | 1 |
| Kobayashi, S | 1 |
| Yamaguchi, M | 1 |
| Nakagawa, H | 1 |
| Hilakivi, LA | 1 |
| Hilakivi, I | 1 |
| Gulati, A | 1 |
| Dhawan, KN | 1 |
| Gupta, GP | 1 |
| Corn, TH | 1 |
| Glass, IB | 1 |
| Blouin, AG | 1 |
| Blouin, JH | 1 |
| Perez, EL | 1 |
| Bushnik, T | 1 |
| Zuro, C | 1 |
| Mulder, E | 1 |
| Molina, VA | 1 |
| Keller, EA | 1 |
| Orsingher, OA | 1 |
| Towell, A | 1 |
| Willner, P | 1 |
| Frank, RG | 1 |
| Kashani, JH | 1 |
| Parker, JC | 1 |
| Beck, NC | 1 |
| Brownlee-Duffeck, M | 1 |
| Elliott, TR | 1 |
| Haut, AE | 1 |
| Atwood, C | 1 |
| Smith, E | 1 |
| Kay, DR | 1 |
| Manfè, AZ | 1 |
| Bonea, M | 1 |
| Da Rold, A | 1 |
| Maffei Faccioli, A | 1 |
| Terranova, O | 1 |
| Yeragani, VK | 1 |
| Patel, H | 1 |
| Keshavan, MS | 1 |
| Renshaw, DC | 1 |
| Brown, R | 1 |
| Kocsis, J | 1 |
| Caroff, S | 1 |
| Winokur, A | 1 |
| Sweeney, J | 1 |
| Stokes, P | 1 |
| Giannini, AJ | 1 |
| Malone, DA | 1 |
| Giannini, MC | 1 |
| Price, WA | 1 |
| Loiselle, RH | 1 |
| Dilsaver, SC | 1 |
| Klysner, R | 1 |
| Otton, SV | 1 |
| Sallee, F | 1 |
| Stiller, R | 1 |
| Perel, J | 1 |
| Rancurello, M | 1 |
| Meador-Woodruff, JH | 1 |
| Grunhaus, L | 1 |
| Mahapatra, RK | 1 |
| Paul, SK | 1 |
| Mahapatra, D | 1 |
| Winter, S | 1 |
| Hingtgen, JN | 1 |
| Fuller, RW | 1 |
| Mason, NR | 1 |
| Aprison, MH | 1 |
| Shipley, JE | 1 |
| Kupfer, DJ | 1 |
| Griffin, SJ | 1 |
| Dealy, RS | 1 |
| Coble, PA | 1 |
| McEachran, AB | 1 |
| Grochocinski, VJ | 1 |
| Ulrich, R | 1 |
| Lieberman, JA | 1 |
| Steinberg, H | 1 |
| Borenstein, M | 1 |
| Brenner, R | 1 |
| Kane, JM | 1 |
| Eisenberg, J | 1 |
| Asnis, G | 1 |
| Webster, PA | 1 |
| Donlon, PT | 1 |
| Blacker, KH | 1 |
| McNair, DM | 1 |
| Segal, DS | 1 |
| Kuczenski, R | 1 |
| Mandell, AJ | 1 |
| Zung, WW | 3 |
| Hawkins, DR | 1 |
| Guilleminault, C | 1 |
| Carskadon, M | 1 |
| Dement, WC | 1 |
| Schanberg, SM | 1 |
| Breese, GR | 1 |
| Kopin, IJ | 1 |
| Ballinger, BR | 1 |
| Presly, A | 1 |
| Reid, AH | 1 |
| Stevenson, IH | 1 |
| Ogura, C | 1 |
| Okuma, T | 1 |
| Uchida, Y | 1 |
| Imai, S | 1 |
| Yogi, H | 1 |
| Pantarott, C | 1 |
| de White, C | 1 |
| Royds, RB | 1 |
| Fawcett, JA | 2 |
| Dekirmenjian, H | 2 |
| Secunda, SK | 1 |
| Dyson, WL | 1 |
| Watt, DC | 1 |
| Crammer, JL | 1 |
| Elkes, A | 1 |
| Tanimukai, H | 1 |
| Berner, P | 1 |
| Kryspin-Exner, K | 1 |
| Alexander, L | 1 |
| Eisenring, JJ | 1 |
| Tissot, R | 1 |
| Yanniotis, G | 1 |
| Tuck, JR | 1 |
| Kahan, E | 1 |
| Falk, MA | 1 |
| Vestre, ND | 1 |
| Janecek, J | 1 |
| Zimmermann, R | 1 |
| Kammerer, M | 1 |
| Wartel, R | 1 |
| Gurfein, L | 1 |
| Weil, J | 1 |
| Wysoki, V | 1 |
| Gelb, F | 1 |
| Bickel, MH | 1 |
| Stewart, JA | 1 |
| Mitchell, PH | 1 |
| Haider, I | 1 |
| Hrdina, P | 1 |
| Maxwell, C | 2 |
| Laitinen, L | 1 |
| Marjerrison, G | 1 |
| Deza, PC | 1 |
| Silzer, JC | 1 |
| Rodová, A | 1 |
| Svestka, J | 1 |
| Náhunek, K | 1 |
| Jones, H | 1 |
| Heller, A | 1 |
| Zahourek, R | 1 |
| Whittington, HG | 1 |
| Sjöqvist, F | 1 |
| Wharton, RN | 1 |
| Dayton, PG | 1 |
| Malitz, S | 1 |
| Fawcett, J | 1 |
| Fischer, E | 1 |
| Spatz, H | 1 |
| Saavedra, JM | 1 |
| Reggiani, H | 1 |
| Miró, AH | 1 |
| Heller, B | 1 |
| Rockliff, BW | 1 |
| Iriye, TT | 1 |
| Simmonds, FA | 1 |
| Luthe, R | 1 |
| dos Reis, MA | 1 |
| Ponte, AV | 1 |
| Edwards, G | 1 |
| Arieff, AJ | 1 |
| Hage, G | 1 |
| Haug, JO | 1 |
| Hargreaves, MA | 1 |
| Fischbach, R | 3 |
| Núnek, K | 1 |
| Ose, E | 1 |
| Consolo, S | 1 |
| Morselli, PL | 1 |
| Zaccala, M | 1 |
| Garattini, S | 1 |
| Wolpowitz, B | 1 |
| Roux, JT | 1 |
| Bertolotti, P | 1 |
| De Pietri, L | 1 |
| Schuckit, M | 1 |
| Robins, E | 1 |
| Feighner, J | 1 |
| Bucher, HW | 1 |
| Stucki, P | 1 |
| Margat, P | 1 |
| Broussot, T | 1 |
| Pouly, JP | 1 |
| Giudicelli, S | 1 |
| Campailla, G | 1 |
| Ascher, J | 1 |
| Bini, A | 1 |
| Liberati, F | 1 |
| Pompili, A | 1 |
| Sinibaldi, L | 1 |
| Vaillant, GE | 1 |
| López-Ibor, JJ | 1 |
| Coullaut, R | 1 |
| López De Lerma, J | 1 |
| Reeves, JE | 1 |
| Lafave, HG | 1 |
| March, BW | 1 |
| Kargas, AK | 1 |
| Shuffler, SY | 1 |
| Rojo Sierra, M | 1 |
| Vencovský, E | 1 |
| Sedivec, V | 1 |
| Peterová, E | 1 |
| Baudis, P | 1 |
| Janovský, F | 1 |
| Valenová, Z | 1 |
| Ayres, CM | 1 |
| Morel-Maroger, A | 1 |
| Levy, S | 1 |
| Grabowski, JR | 1 |
| Boittelle, G | 1 |
| Boittelle-Lentulo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology[NCT02659787] | 38 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| [NCT00265291] | Phase 2 | 700 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device[NCT00578383] | 107 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Low Field Magnetic Stimulation in Bipolar Depression[NCT00217217] | Phase 3 | 13 participants (Actual) | Interventional | 2004-09-30 | Terminated (stopped due to Study was terminated for lack of recruitment.) | ||
| Low Field Magnetic Stimulation in Mood Disorders in Six Visits[NCT01557192] | Phase 1 | 200 participants (Anticipated) | Interventional | 2010-05-31 | Suspended (stopped due to on hold indefinitely due to lack of funding) | ||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.[NCT03314155] | 60 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, and Want More. The Feel Drug, Feel High, Like Drug, and Want More subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT02659787)
Timeframe: 0 through 3 hours after dosing.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Feel Drug | Like Drug | Feel High | Want More | |
| Low Dose Buprenorphine | 21.03 | 23.09 | 10.91 | 17.46 |
| Placebo | 10.64 | 19.8 | 5.74 | 16.76 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -7.19 |
| Major Depressive Disorder Sham LFMS Treatment | -4.02 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -8.3 |
| Bipolar Disorder Sham LFMS Treatment | -5.79 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Group Active LFMS Treatment | -8.13 |
| Combined Group Sham LFMS Treatment | -5.02 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -7.66 |
| Bipolar Disorder Sham LFMS Treatment | -6.31 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -5.28 |
| Major Depressive Disorder Sham LFMS Treatment | -3.04 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Groups Active LFMS Treatment | -7.00 |
| Combined Groups Sham LFMS Treatment | -5.00 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | 4.18 |
| Bipolar Disorder Sham LFMS Treatment | -0.79 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | 1.05 |
| Major Depressive Disorder Sham LFMS Treatment | -0.63 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Groups Active LFMS Treatment | 3.16 |
| Combined Groups Sham LFMS Treatment | -0.94 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -1.18 |
| Bipolar Disorder Sham LFMS Treatment | -1.05 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -1.33 |
| Major Depressive Disorder Sham LFMS Treatment | 0.25 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Group Active LFMS Treatment | -1.66 |
| Combined Groups Sham LFMS Treatment | -0.60 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
22 reviews available for desipramine and Depression
| Article | Year |
|---|---|
Factors influencing behavior in the forced swim test.
Topics: Aging; Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Conditioning, Psychological; D | 2013 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dop | 2011 |
Pharmacologic treatment of depression in multiple sclerosis.
Topics: Adult; Antidepressive Agents; Depression; Desipramine; Humans; Multiple Sclerosis; Paroxetine; Rando | 2011 |
CURRENT STATUS OF DRUG TREATMENT IN THE DEPRESSIVE STATE.
Topics: Amitriptyline; Amphetamine; Amphetamines; Antidepressive Agents; Aspartic Acid; Benactyzine; Classif | 1964 |
THE PHARMACOTHERAPY OF THE DEPRESSIVE SYNDROME.
Topics: Amitriptyline; Antidepressive Agents; Convulsive Therapy; Depression; Depressive Disorder; Desiprami | 1965 |
THE ANTIDEPRESSANT DRUGS.
Topics: Amitriptyline; Antidepressive Agents; Central Nervous System Stimulants; Depression; Depressive Diso | 1965 |
The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Desipramine; Doxepin; Heart; Humans; Im | 1980 |
Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Cardiovascular S | 1982 |
Clinical and biochemical heterogeneity of depressive disorders.
Topics: Amitriptyline; Animals; Antidepressive Agents; Brain; Depression; Desipramine; Dextroamphetamine; Em | 1978 |
Tricyclic antidepressants (first of two parts).
Topics: Aged; Amines; Amitriptyline; Antidepressive Agents, Tricyclic; Chemical Phenomena; Chemistry; Child; | 1978 |
Pharmacology of locus coeruleus spontaneous and sensory-evoked activity.
Topics: 1-Naphthylamine; Action Potentials; Animals; Antidepressive Agents; Corticotropin-Releasing Hormone; | 1991 |
A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review.
Topics: Animals; Cardiovascular System; Chemical Phenomena; Chemistry; Depression; Desipramine; Dibenzazepin | 1987 |
Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depressio | 1986 |
Self-evaluations of antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Chlordiazepoxide; Clinical Trials as Topic; Depression; Desipr | 1974 |
Antidepressant drugs and sleep.
Topics: Adult; Amitriptyline; Animals; Antidepressive Agents; Arousal; Brain; Cats; Depression; Desipramine; | 1969 |
The pharmacology of disordered sleep: a laboratory approach.
Topics: Amitriptyline; Anxiety; Arousal; Barbiturates; Brain; Cerebral Cortex; Depression; Desipramine; Huma | 1970 |
The clinical pharmacology of imipramine. Implications for therapeutics.
Topics: Administration, Oral; Barbiturates; Cell Membrane Permeability; Depression; Desipramine; Drug Intera | 1973 |
[Appraisal of pharmacotherapy of affective disorders].
Topics: Adolescent; Depression; Desipramine; Female; Humans; Imipramine; Male; Middle Aged; Monoamine Oxidas | 1973 |
MHPG excretion by patients with affective disorders.
Topics: Affective Symptoms; Bipolar Disorder; Brain; Catecholamines; Creatinine; Depression; Desipramine; De | 1974 |
[Studies on the biochemistry and pharmacology of thymoleptics].
Topics: Amines; Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Catecholamines; Cats; Dep | 1968 |
[Pharmacology of antidepressive agents of the imipramine type].
Topics: Antidepressive Agents; Catecholamines; Depression; Desipramine; Humans | 1968 |
Indications for tricyclic antidepressant drugs.
Topics: Antidepressive Agents; Chlorpromazine; Depression; Desipramine; Drug Interactions; Humans; Imipramin | 1971 |
60 trials available for desipramine and Depression
| Article | Year |
|---|---|
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
Topics: Adult; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Colonic Diseases, Functional; | 2003 |
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Desipramine; Double-Blind Method; Female; Human | 2008 |
Alpha 2 adrenergic receptors in depression.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Desipramine; Humans; Recepto | 1982 |
Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness.
Topics: Adolescent; Adult; Ambulatory Care; Clinical Trials as Topic; Depression; Depressive Disorder; Desip | 1983 |
Impact of suppression of thyroxine on folate status during acute antidepressant therapy.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Depression; | 1998 |
Cardiovascular effects of desipramine in children and adults during exercise testing.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Blood Pressu | 1999 |
Pharmacological modification of experimental depression in infant macaques.
Topics: Animals; Anxiety, Separation; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Fem | 1979 |
Comparative clinical evaluation of lofepramine and imipramine. Pharmacological aspects.
Topics: Adult; Chromatography, Gas; Clinical Trials as Topic; Depression; Desipramine; Drug Evaluation; Fema | 1977 |
Antidepressant effects of desipramine adminstered in two dosage schedules.
Topics: Adolescent; Adult; Blood Pressure; Clinical Trials as Topic; Depression; Desipramine; Drug Administr | 1977 |
A comparative trial of Anafranil, Pertofran and an Anafranil/Pertofran combination.
Topics: Adolescent; Adult; Clinical Trials as Topic; Clomipramine; Depression; Desipramine; Dibenzazepines; | 1977 |
[Double-blind trial of 2 antidepressive drugs].
Topics: Clinical Trials as Topic; Depression; Desipramine; Double-Blind Method; Drug Evaluation; Humans; Mor | 1977 |
Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic antidepressant drugs.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bethanidine; Blood Pressure; Cardiovascular | 1978 |
Desipramine plasma levels and therapeutic response.
Topics: Adult; Clinical Trials as Topic; Depression; Desipramine; Double-Blind Method; Female; Humans; Male; | 1978 |
A comparison of desipramine and amitriptyline plasma levels and therapeutic response.
Topics: Adjustment Disorders; Adult; Amitriptyline; Clinical Trials as Topic; Depression; Desipramine; Doubl | 1978 |
Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Biopharmaceutics; Clinical Trials as Topic; | 1978 |
[Differential indications for desipramine--results of a controlled multiclinical study].
Topics: Clinical Trials as Topic; Depression; Desipramine; Double-Blind Method; Humans; Imipramine | 1978 |
Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism.
Topics: Adult; Bipolar Disorder; Brain; Clinical Trials as Topic; Depression; Desipramine; Double-Blind Meth | 1978 |
Desipramine plasma levels and clinical response in depressed outpatients.
Topics: Adult; Amitriptyline; Clinical Trials as Topic; Depression; Desipramine; Double-Blind Method; Female | 1979 |
Plasma levels and antidepressive effect of imipramine.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Imi | 1976 |
[Fast-acting antidepressive agents: comparison of trazodone and desipramine in a controlled double-blind trial].
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Desipramine; Drug Evaluation; Female; Humans; Mal | 1975 |
A double blind comparative trial of nomifensin and desimipramine in depression. Relationship between treatment and phenylethylamine excretion.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Iso | 1976 |
[Experiences with Petylyl (desipramine) in antidepressive therapy. Double blind test with Pryleugan (imipramine)].
Topics: Clinical Trials as Topic; Depression; Desipramine; Drug Evaluation; Humans; Imipramine | 1976 |
Pharmacodynamics of imipramine in depressed patients.
Topics: Clinical Trials as Topic; Depression; Desipramine; Half-Life; Humans; Imipramine; Phenylbutazone | 1975 |
Tricyclic antidepressants and tryptophan in unipolar depression.
Topics: Clomipramine; Depression; Desipramine; Dibenzazepines; Drug Therapy, Combination; Female; Humans; Ma | 1975 |
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa | 1992 |
Depression as a prognostic factor for pharmacological treatment of cocaine dependence.
Topics: Adult; Amantadine; Cocaine; Depression; Desipramine; Female; Humans; Male; Prognosis; Psychiatric St | 1991 |
Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial.
Topics: Adult; Aged; Benztropine; Depression; Desipramine; Diabetic Neuropathies; Double-Blind Method; Emoti | 1991 |
Desipramine treatment of alcoholism.
Topics: Adult; Alcoholism; Depression; Desipramine; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1991 |
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Topics: Depression; Desipramine; Diabetic Neuropathies; Humans; Imipramine; Nervous System; Osmolar Concentr | 1990 |
A controlled trial of adinazolam versus desipramine in geriatric depression.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aging; Anti-Anxiety Agents; Antidepressive Agents; Be | 1990 |
A controlled trial of desipramine in 18 men with posttraumatic stress disorder.
Topics: Adult; Clinical Trials as Topic; Depression; Desipramine; Double-Blind Method; Humans; Male; Middle | 1989 |
Treatment of bulimia with fenfluramine and desipramine.
Topics: Adolescent; Adult; Body Weight; Bulimia; Clinical Trials as Topic; Depression; Desipramine; Double-B | 1988 |
Antidepressant analgesia in rheumatoid arthritis.
Topics: Aged; Amitriptyline; Antidepressive Agents; Arthritis, Rheumatoid; Depression; Desipramine; Double-B | 1988 |
Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine.
Topics: Adult; Clinical Trials as Topic; Cocaine; Depression; Desipramine; Humans; Male; Phencyclidine; Plac | 1986 |
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Debrisoquin; Depression; Desipramine; Fema | 1986 |
Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients.
Topics: Adult; Amitriptyline; Depression; Desipramine; Double-Blind Method; Electroencephalography; Female; | 1985 |
Tricyclic antidepressants and tryptophan in unipolar affective disorder.
Topics: Affective Symptoms; Antidepressive Agents; Depression; Desipramine; Evaluation Studies as Topic; Hum | 1972 |
Self-evaluations of antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Chlordiazepoxide; Clinical Trials as Topic; Depression; Desipr | 1974 |
Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.
Topics: Adult; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Blood Pressure; Depression; Desipr | 1974 |
Catecholamine metabolism, depressive illness, and drug response.
Topics: Adult; Aged; Brain; Brain Chemistry; Catechols; Clinical Trials as Topic; Depression; Desipramine; E | 1972 |
A controlled study of the antidepressant effects of lithium carbonate.
Topics: Adult; Age Factors; Analysis of Variance; Bipolar Disorder; Carbonates; Clinical Trials as Topic; De | 1972 |
Metabolism, anticholinergic effects, and therapeutic outcome of desmethylimipramine in depressive illness.
Topics: Adult; Aged; Body Weight; Clinical Trials as Topic; Depression; Desipramine; Dose-Response Relations | 1972 |
Therapy possibilities for therapy-resistant depressions.
Topics: Amitriptyline; Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Depression; Desipra | 1974 |
A controlled study of desipramine in the treatment of hospitalized depressive disorders.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depression; Desipramine; Female | 1967 |
Treatment of depression. A comparative trial of imipramine and desipramine.
Topics: Adult; Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Imipramine; Male | 1967 |
[Clinical experimentation with desipramine with statistical control].
Topics: Adult; Aged; Anorexia Nervosa; Barbiturates; Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Cli | 1968 |
A comparative trial of desipramine and nortriptyline in depression.
Topics: Adolescent; Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Desipramine; Electroconvulsi | 1968 |
A comparative investigation of desipramine and nortriptyline in the treatment of depression.
Topics: Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Male; Middl | 1968 |
Depression: prognosis and drug treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Clinical Trials as Topic; Depression; Desipramine; Female; Hum | 1969 |
Desipramine in treatment of Parkinson's disease. A placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Desipramine; Drug Synergism; Fatigue; Gait; Human | 1969 |
Verbal behaviour changes with depression treatment.
Topics: Adolescent; Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Clinical Trials as To | 1969 |
[Clinical experience with desipramine in endogenous and involutional depressions].
Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Des | 1970 |
Placebo-control evaluation of desipramine in depression.
Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Depression; Desip | 1970 |
Effectiveness of antidepressant drugs: a triple-blind study comparing imipramine, desipramine, and placebo.
Topics: Clinical Trials as Topic; Depression; Desipramine; Humans | 1971 |
A pharmacokinetic approach to the treatment of depression.
Topics: Barbiturates; Biotransformation; Blood Pressure; Chromatography, Gas; Clinical Trials as Topic; Deal | 1971 |
Depression and MHPG excretion. Response to dextroamphetamine and tricyclic antidepressants.
Topics: Adult; Affect; Antidepressive Agents; Brain Chemistry; Catechols; Depression; Desipramine; Dextroamp | 1972 |
Comparison of the effect of imipramine and desipramine on some symptoms of depressive illness.
Topics: Adult; Anorexia Nervosa; Anxiety; Clinical Trials as Topic; Depression; Desipramine; Humans; Imipram | 1965 |
Desipramine and nortriptyline in mental depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Desipramine; Humans; Nortriptyline | 1966 |
[Clinical trials with Sertofren in depression].
Topics: Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Male | 1965 |
The speed of action of desipramine: a controlled trial.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Desipramine; Female; Humans; Imipramine; Mi | 1967 |
259 other studies available for desipramine and Depression
| Article | Year |
|---|---|
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Desipramine restores the alterations in circadian entrainment induced by prenatal exposure to glucocorticoids.
Topics: Animals; Antidepressive Agents, Tricyclic; Circadian Rhythm; Depression; Desipramine; Dexamethasone; | 2019 |
Effect of concurrent organic cation transporter blockade on norepinephrine clearance inhibiting- and antidepressant-like actions of desipramine and venlafaxine.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Dentate Gyrus; Depre | 2020 |
Facilitation of dopamine-dependent long-term potentiation in the medial prefrontal cortex of male rats follows the behavioral effects of stress.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dopamine; Elevated Plus Maze Test; | 2021 |
Unravelling the antimicrobial action of antidepressants on gut commensal microbes.
Topics: Akkermansia; Antidepressive Agents; Bacteroides fragilis; Bifidobacterium animalis; Depression; Desi | 2020 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Reg | 2021 |
Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABA
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dose | 2017 |
Desipramine rescues age-related phenotypes in depression-like rats induced by chronic mild stress.
Topics: Aging; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desipramine; Eating; | 2017 |
Depressive-like phenotype induced by prenatal dexamethasone in mice is reversed by desipramine.
Topics: Animals; Antidepressive Agents, Tricyclic; Dendrites; Depression; Desipramine; Dexamethasone; Female | 2017 |
Effects of the antidepressants desipramine and fluvoxamine on latency to immobility and duration of immobility in the forced swim test in adult male C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desi | 2018 |
Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Behavior, Animal; Brain; | 2013 |
Effects of chronic antidepressant treatments in a putative genetic model of vulnerability (Roman low-avoidance rats) and resistance (Roman high-avoidance rats) to stress-induced depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Avoidance Learning; Behavior, Anim | 2014 |
1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous Neuroprotectant and MAO inhibitor with antidepressant-like properties in the rat.
Topics: Animals; Antidepressive Agents; Corpus Striatum; Depression; Desipramine; Dopamine; Dose-Response Re | 2014 |
Effects of chronic desipramine pretreatment on open field-induced suppression of blood natural killer cell activity and cytokine response depend on the rat's behavioral characteristics.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Cytokines; Depression; Desipramine; Dis | 2014 |
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Brain; Depressi | 2014 |
Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Cognition Disorders; Depression; Desipramine; Fear; Homeodoma | 2014 |
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; De | 2015 |
Effect of antidepressant drugs on the vmPFC-limbic circuitry.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain Injuries; Cell Count; Depression; Desipr | 2015 |
Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder, Major | 2015 |
Involvement of serotonin 2C receptor RNA editing in accumbal neuropeptide Y expression and behavioural despair.
Topics: Aggression; Animals; Antidepressive Agents, Tricyclic; Anxiety; Depression; Desipramine; Male; Mice; | 2016 |
Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression.
Topics: Age Factors; Animals; Animals, Newborn; Anti-Anxiety Agents; Corpus Striatum; Cytokines; Depression; | 2017 |
Adolescent chronic restraint stress (aCRS) elicits robust depressive-like behavior in freely cycling, adult female rats without increasing anxiety-like behaviors.
Topics: Age Factors; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Depressive Dis | 2017 |
Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desipramine; Humans; Mice; | 2008 |
Abstinence following alcohol drinking produces depression-like behavior and reduced hippocampal neurogenesis in mice.
Topics: Alcohol Drinking; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Cell Survival; Centra | 2009 |
Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Synergistic effects of stress and omega-3 fatty acid deprivation on emotional response and brain lipid composition in adult rats.
Topics: Animals; Animals, Newborn; Arachidonic Acid; Behavior, Animal; Body Weight; Brain Chemistry; Depress | 2008 |
Desipramine potentiation of the acute depressant effects of ethanol: modulation by alpha2-adrenoreceptors and stress.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Body Temp | 2008 |
Desipramine blocks alcohol-induced anxiety- and depressive-like behaviors in two rat strains.
Topics: Administration, Inhalation; Animals; Antidepressive Agents, Tricyclic; Anxiety; Body Weight; Central | 2008 |
Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; D | 2008 |
Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Des | 2008 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Antidepressant-like effects of echo-planar magnetic resonance imaging in mice determined using the forced swimming test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Desipramine; Dis | 2008 |
Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats.
Topics: Acid Ceramidase; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Apoptosis; Ceramid | 2009 |
Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-An | 2009 |
Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Biomarkers, Pharmacological; Co | 2009 |
Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Codeine; Depression; Desiprami | 2009 |
Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety.
Topics: Acetylation; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; A | 2009 |
The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; De | 2010 |
Alcohol reverses depressive and pronociceptive effects of chronic stress in mice with enhanced activity of the opioid system.
Topics: Alcohol Drinking; Analgesics, Opioid; Analysis of Variance; Animals; Antidepressive Agents, Tricycli | 2009 |
Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine.
Topics: Anesthetics, Dissociative; Antidepressive Agents, Tricyclic; Depression; Desipramine; Dose-Response | 2010 |
Antidepressant-like action of intracerebral 6-fluoronorepinephrine, a selective full α-adrenoceptor agonist.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antidepressive Agents; Behavior, Animal; Brain; Depre | 2011 |
Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression.
Topics: Animals; Antidepressive Agents; Benzamides; Depression; Desipramine; Disease Models, Animal; Dose-Re | 2010 |
Effects of antidepressants on the performance in the forced swim test of two psychogenetically selected lines of rats that differ in coping strategies to aversive conditions.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Clomipramine; Depression; Desi | 2010 |
Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agen | 2010 |
Further evidence for an immediate antidepressant action of intracerebral drug administration in a model of chronic depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depression; Depressive Disorder; Desipramin | 2011 |
Acute desipramine treatment reduces regional serotonin synthesis rates, while chronic treatment elevates rates, in a rat model of depression: an autoradiographic study.
Topics: Animals; Antidepressive Agents, Tricyclic; Autoradiography; Depression; Desipramine; Disease Models, | 2011 |
The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo.
Topics: Animals; Antidepressive Agents, Tricyclic; Arrestins; Depression; Desipramine; Down-Regulation; Drug | 2011 |
Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Brain; Chromatography, High Pressure Liqui | 2012 |
Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor.
Topics: Animals; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Corticotropin-Releasing Hormone; | 2012 |
Hippocampal group III mGlu receptor mRNA levels are not altered in specific mouse models of stress, depression and antidepressant action.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Disease Models, Animal; Gene Expression Reg | 2013 |
Aberrant light directly impairs mood and learning through melanopsin-expressing neurons.
Topics: Affect; Animals; Antidepressive Agents; Body Temperature Regulation; Circadian Rhythm; Cognition; Co | 2012 |
A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.
Topics: Animals; Antidepressive Agents; BCG Vaccine; Chronic Disease; Depression; Desipramine; Diazepam; Dis | 2013 |
The antidepressant-like effect induced by the sigma(1) (sigma(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization.
Topics: Adrenalectomy; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; C | 2002 |
Genotype- and experience-dependent susceptibility to depressive-like responses in the forced-swimming test.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents, Tri | 2002 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Gene | 2002 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An | 2003 |
Clinical trial with desmethylimipramine (G-35020), a new antidepressive compound.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Imipramine | 1962 |
THE USE OF "PERTOFRAN" IN DEPRESSION: A SHORT COMMUNICATION.
Topics: Communication; Depression; Depressive Disorder; Desipramine; Humans; Imipramine | 1963 |
COMBINED ADMINISTRATION OF DESIPRAMINE AND RESERPINE OR TETRABENAZINE IN DEPRESSIVE PATIENTS.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Humans; Imipramine; Reserpine; | 1963 |
COMPARISON BETWEEN IMIPRAMINE AND DESIPRAMINE IN NORMAL SUBJECTS AND THEIR ACTION IN DEPRESSIVE PATIENTS.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Humans; Imipramine | 1963 |
TREATMENT OF SEVERE DEPRESSION WITH DESIPRAMINE, A METABOLITE OF IMIPRAMINE.
Topics: Adolescent; Antidepressive Agents; Brain Diseases; Depression; Depressive Disorder; Depressive Disor | 1963 |
[TREATMENT OF DEPRESSED PATIENTS WITH PERTOFRANE. PRELIMINARY REPORT].
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Humans | 1963 |
[DESMETHYLIMIPRAMINE (PERTOFRAN) IN THE TREATMENT OF DEPRESSIONS. A CLINICAL AND PSYCHODYNAMIC APPRAISAL].
Topics: Antidepressive Agents; Biomedical Research; Bipolar Disorder; Chlorpromazine; Depression; Depressive | 1963 |
[PRELIMINARY OBSERVATIONS ON THE CLINICAL USE OF A METABOLITE OF IMIPRAMINE: DESMETHYLIMIPRAMINE (G 35020)].
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Humans; Imipramine; Mental Diso | 1963 |
[DESIPRAMINE (PERTOFRAN) IN THE TREATMENT OF DEPRESSIONS WITH A PSYCHODYNAMIC ANALYSIS OF ITS THERAPEUTIC EFFECTS].
Topics: Antidepressive Agents; Biomedical Research; Bipolar Disorder; Depression; Depressive Disorder; Desip | 1964 |
[ON THE THERAPEUTIC EFFECTS AND SIGNIFICANCE OF A NEW ANTIDEPRESSIVE AGENT, DESMETHYLIMIPRAMINE (PERTOFRAN)].
Topics: Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Drug Therapy; Humans | 1964 |
COMPARISON OF DESIPRAMINE AND IMIPRAMINE IN DEPRESSION.
Topics: Biomedical Research; Depression; Depressive Disorder; Desipramine; Drug Therapy; Imipramine; Toxicol | 1964 |
TREATMENT OF SEVERE DEPRESSION WITH DESIPRAMINE: LONG-TERM TRIAL AND FOLLOW-UP.
Topics: Constipation; Depression; Depressive Disorder; Depressive Disorder, Major; Desipramine; Drug Hyperse | 1964 |
[PROGRESS OF DEPRESSIVE DISEASES UNDER DRUG THERAPY].
Topics: Amitriptyline; Antidepressive Agents; Depression; Depressive Disorder; Desipramine; Drug Therapy; Hu | 1964 |
DESIPRAMINE IN THE TREATMENT OF LONG STANDING PSYCHOTIC DISORDERS.
Topics: Depression; Desipramine; Drug Therapy; Hypnotics and Sedatives; Phenothiazines; Psychotic Disorders; | 1965 |
CLINICAL TRIAL OF DESIPRAMINE IN THE TREATMENT OF DEPRESSION.
Topics: Brain; Brain Damage, Chronic; Brain Injuries; Depression; Depressive Disorder; Desipramine; Drug The | 1965 |
CLINICAL TRIAL OF A NEW ANTIDEPRESSANT (DESIPRAMINE HYDROCHLORIDE) IN A HOSPITAL SETTING.
Topics: Antidepressive Agents; Biomedical Research; Bipolar Disorder; Depression; Depressive Disorder; Desip | 1965 |
THE DIAGNOSIS AND MANAGEMENT OF DEPRESSION.
Topics: Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Classification; Depression; Depre | 1965 |
THE MANAGEMENT OF DEPRESSION IN HOSPITAL. A COMPARATIVE TRIAL OF DESIPRAMINE AND IMIPRAMINE.
Topics: Biomedical Research; Depression; Depressive Disorder; Desipramine; Drug Therapy; Humans; Imipramine; | 1965 |
SIDE-EFFECTS OF PERTOFRAN.
Topics: Depression; Desipramine; Drug Therapy; Epilepsy; Epilepsy, Tonic-Clonic; Seizures; Toxicology | 1965 |
Desmethylimipramine (G-35020) in the treatment of depression, pilot study in a general hospital and outpatient setting.
Topics: Depression; Depressive Disorder; Desipramine; Hospitals, General; Imipramine; Outpatients; Pilot Pro | 1962 |
Preliminary investigation of desmethylimipramine (G 35020).
Topics: Depression; Depressive Disorder; Desipramine; Imipramine | 1962 |
Desipramine treatment reduces the long-term behavioural and neurochemical sequelae of early-life maternal separation.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Dent | 2003 |
Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2004 |
Total sleep deprivation decreases immobility in the forced-swim test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; | 2004 |
Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Disease Models, Animal; Dose-Response Relat | 2004 |
Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cita | 2004 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Drox | 2004 |
Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.
Topics: Adult; Cytochrome P-450 CYP2D6; Depression; Desipramine; Double-Blind Method; Fluoxetine; Humans; Hy | 2004 |
Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; D | 2004 |
Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior.
Topics: Animals; Autoradiography; Brain; Depression; Desipramine; DNA Mutational Analysis; Female; Fluoxetin | 2005 |
Magnesium-deficient diet alters depression- and anxiety-related behavior in mice--influence of desipramine and Hypericum perforatum extract.
Topics: Animals; Anxiety; Depression; Desipramine; Hypericum; Locomotion; Magnesium Deficiency; Mice; Mice, | 2004 |
Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Mo | 2005 |
Variability of the mesolimbic neuronal activity in a rat model of depression.
Topics: Action Potentials; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desipram | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Ejaculation induces long-lasting behavioural changes in male rats in the forced swimming test: evidence for an increased sensitivity to the antidepressant desipramine.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desip | 2005 |
Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide.
Topics: alpha-MSH; Analysis of Variance; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic | 2005 |
Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models.
Topics: Activins; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; | 2005 |
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.
Topics: Acetamides; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticost | 2005 |
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2007 |
Resolving the onset of antidepressants' clinical actions: critical for clinical practice and new drug development.
Topics: Affect; Animals; Antidepressive Agents; Clinical Trials as Topic; Depression; Desipramine; Drug Desi | 2006 |
Reduced evoked fos expression in activity-related brain regions in animal models of behavioral depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Desipramine; Dis | 2007 |
The use of a tricyclic antidepressant in epilepsy.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Depression; Desipramine; Epilepsy, Temporal Lobe; | 1974 |
Increased water temperature renders single-housed C57BL/6J mice susceptible to antidepressant treatment in the forced swim test.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Corticosterone; Data Interpretatio | 2008 |
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.
Topics: Adaptation, Psychological; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticos | 2008 |
An anti-immobility effect of exogenous corticosterone in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Desipramine; Disease M | 2008 |
Light deprivation damages monoamine neurons and produces a depressive behavioral phenotype in rats.
Topics: Animals; Apoptosis; Behavior, Animal; Biogenic Amines; Body Weight; Darkness; Depression; Desipramin | 2008 |
Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Brain; Depressio | 2008 |
The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat.
Topics: Animals; Antidepressive Agents, Tricyclic; Conditioning, Operant; Depression; Desipramine; Food; Inf | 2008 |
Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats.
Topics: Administration, Oral; Alginates; Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Depres | 2008 |
Lack of persistent effects of ketamine in rodent models of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Apomorphine; Cerebral Cortex; Depr | 2008 |
[Psychopathological complications in antidepressant medication].
Topics: Amitriptyline; Animals; Antidepressive Agents; Blood Pressure; Delirium; Depression; Desipramine; Do | 1966 |
[Therapeutic experiences in 5 clinics with a dibenzoxepine derivative in depressive states].
Topics: Amitriptyline; Depression; Desipramine; Dibenzothiepins; Dibenzoxepins; Humans; Imipramine; Monoamin | 1966 |
[Comparative clinical experiences with Protriptyline in depressive conditions of various origins].
Topics: Amitriptyline; Antidepressive Agents; Depression; Desipramine; Dibenzazepines; Humans; Imipramine; N | 1966 |
[Therapeutic trials with pertofran (G. 35-020) in depressive states].
Topics: Depression; Desipramine; Humans; Psychotic Disorders | 1967 |
[Clinical studies of a new antidepressive agent, nortriptyline].
Topics: Adolescent; Adult; Aged; Amitriptyline; Depression; Desipramine; Humans; Imipramine; Middle Aged; Ne | 1967 |
Dexamethasone suppression test identifies subtypes of depression which respond to different antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Clomipramine; Depression; Depression, Chemic | 1980 |
Down-regulation at pineal beta-adrenoceptors in depressed patients treated with desipramine.
Topics: Depression; Desipramine; Humans; Pineal Gland; Receptors, Adrenergic; Receptors, Adrenergic, beta; S | 1983 |
Pineal beta-adrenoreceptor down-regulation by desipramine in depression.
Topics: Depression; Desipramine; Humans; Pineal Gland; Receptors, Adrenergic; Receptors, Adrenergic, beta | 1983 |
Down-regulation at pineal beta-adrenoceptors in depressed patients treated with desipramine?
Topics: Animals; Depression; Desipramine; Humans; Melatonin; Pineal Gland; Receptors, Adrenergic; Receptors, | 1983 |
The effect of acute and chronic administration of desmethylimipramine on responses to stress in rats.
Topics: Acute Disease; Animals; Anorexia; Chronic Disease; Corticosterone; Depression; Desipramine; Electros | 1984 |
Endogenous depression and imipramine levels in the blood.
Topics: Adult; Aged; Depression; Desipramine; Female; Humans; Imipramine; Kinetics; Male; Middle Aged; Psych | 1980 |
The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.
Topics: Debrisoquin; Depression; Desipramine; Humans; Hydroxylation | 1983 |
An inverse correlation between serum levels of desmethylimipramine and melatonin-like immunoreactivity in DMI-responsive depressives.
Topics: Adolescent; Adult; Aged; Depression; Depressive Disorder; Desipramine; Female; Humans; Male; Melaton | 1981 |
Altered hydroxydesipramine concentrations in elderly depressed patients.
Topics: Adult; Aged; Aging; Depression; Desipramine; Female; Humans; Kidney; Male; Middle Aged | 1982 |
Increased intracranial self-stimulation in rats after long-term administration of desipramine.
Topics: Animals; Depression; Desipramine; Dopamine; Humans; Limbic System; Male; Rats; Rats, Inbred Strains; | 1981 |
Clinical response, plasma levels and pharmacokinetics of desipramine in depressed in-patients.
Topics: Adult; Aged; Depression; Desipramine; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Psychi | 1980 |
Plasma desipramine levels after single dosage and at steady state in outpatients.
Topics: Adult; Body Weight; Depression; Desipramine; Humans; Time Factors | 1980 |
The depression-pain syndrome and its response to antidepressants.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Depression; Desipramine; Doxepin; Fem | 1981 |
Electrocardiogram changes and plasma desipramine levels during treatment of depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Pressure; Depression; Desipramine; Electrocardiograph | 1980 |
Quantitative analysis for tricyclic antidepressant drugs in plasma or serum by gas chromatography-chemical-ionization mass spectrometry.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Desipramine; Female; Gas Chromat | 1980 |
Efficacy of desmethylimipramine in endogenomorphically depressed patients.
Topics: Adolescent; Adult; Depression; Desipramine; Female; Humans; Male; Middle Aged; Psychiatric Status Ra | 1980 |
Effects of desipramine and alprazolam on forced swimming behaviour of adult rats exposed to prenatal diazepam.
Topics: Alprazolam; Animals; Behavior, Animal; Depression; Desipramine; Diazepam; Electroencephalography; El | 1995 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catec | 1995 |
Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients.
Topics: Adult; Cholestyramine Resin; Depression; Desipramine; Drug Interactions; Female; Humans; Imipramine; | 1994 |
Juvenile desipramine reduces adult sensitivity to imipramine in two behavioral tests.
Topics: Animals; Behavior, Animal; Defecation; Depression; Desipramine; Female; Imipramine; Motor Activity; | 1993 |
Study addresses question of preferred initial therapy for depression.
Topics: Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depression; Desipramine; Drug Costs; Fluoxe | 1996 |
SSRI or tricyclics for depression?
Topics: Adult; Depression; Depressive Disorder; Desipramine; Family Practice; Fluoxetine; Humans; Imipramine | 1996 |
Potential antidepressant effects of lemon odor in rats.
Topics: Animals; Antidepressive Agents; Citrus; Depression; Desipramine; Imipramine; Male; Motor Activity; O | 1995 |
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Hallucinogens; Hydroxyindoleacetic Acid; Ma | 1997 |
Comparison of rats selectively bred for high and low ethanol intake in a forced-swim-test model of depression: effects of desipramine.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Male; | 1997 |
High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desi | 1997 |
Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment.
Topics: Adrenal Glands; Animals; Antidepressive Agents, Tricyclic; Ascorbic Acid; Corticosterone; Depression | 1998 |
Individual differences in response to imipramine in the mouse tail suspension test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 1997 |
Effects of melatonin receptor ligands on swim test immobility.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body Temperature; Cyclopropanes; D | 1998 |
The need for cautiously extrapolating results obtained with normal animals (healthy individuals) to depressed ones.
Topics: Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Models, Animal; Humans; | 1998 |
Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Depression; Desipramine; Hippocampus; Injectio | 1998 |
Potentiation of ethanol effects in cerebellum by activation of endogenous noradrenergic inputs.
Topics: Adrenergic Uptake Inhibitors; Animals; Ataxia; Central Nervous System Depressants; Cerebellum; Depre | 1999 |
An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression.
Topics: Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Dose-Response Relationship, Drug | 1999 |
Patient's discharge linked to end of insurance coverage. Muse v. Charter Hospital of Winston-Salem, Inc.
Topics: Adolescent; Depression; Desipramine; Drug Overdose; Humans; Insurance, Hospitalization; Liability, L | 1995 |
Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Brain Mapping; Catecholamines; | 1999 |
Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain Chemistry; Depression; Desipramin | 1999 |
SAMe for depression.
Topics: Administration, Oral; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Clinical Tri | 1999 |
Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment.
Topics: Adrenal Cortex; Animals; Antidepressive Agents, Tricyclic; Ascorbic Acid; Behavior, Animal; Corticos | 2000 |
Long photoperiod regimen may produce antidepressant actions in the male rat.
Topics: Animals; Antidepressive Agents, Tricyclic; Clomipramine; Conditioning, Operant; Depression; Desipram | 2000 |
TCAs or SSRIs as initial therapy for depression?
Topics: Adult; Antidepressive Agents, Tricyclic; Costs and Cost Analysis; Depression; Depressive Disorder; D | 1999 |
The differential effects of calcium channel blockers in the behavioural despair test in mice.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Clomipramine; Clonidine; Cyproheptadine; D | 2000 |
Modifications in brain CaM kinase II after long-term treatment with desmethylimipramine.
Topics: Animals; Brain; Brain Chemistry; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calciu | 2001 |
Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Des | 2001 |
Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; | 2001 |
Mimosa pudica may possess antidepressant actions in the rat.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Clomipramine; Depression; Desipramine; Fabaceae; M | 1999 |
Antidepressant reversal of interferon-alpha-induced anhedonia.
Topics: Animals; Antidepressive Agents; Antiviral Agents; Depression; Desipramine; Drinking Behavior; Drug A | 2002 |
The neuropharmacology of depression.
Topics: Amitriptyline; Brain; Brain Chemistry; Depression; Desipramine; Dopamine; Humans; Imipramine; Models | 1977 |
High dose desipramine, plasma drug levels and clinical response.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholestasis; Depression; De | 1979 |
Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data.
Topics: Depression; Desipramine; Drug Administration Schedule; Female; Humans; Imipramine; Kinetics; Male; M | 1979 |
Effects of triiodothyronine on drug levels and cardiac function in depressed patients treated with imipramine.
Topics: Adult; Depression; Desipramine; Female; Heart Conduction System; Heart Rate; Humans; Imipramine; Mid | 1979 |
The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Bundle- | 1979 |
Effects of somatic treatments on mood in endogenous depression.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Clomipramine; Depression; Desipramine | 1979 |
Plasma levels of imipramine (IMI) and desmethylimipramine (DMI) and clinical response in prepubertal major depressive disorder: a preliminary report.
Topics: Child; Depression; Desipramine; Female; Humans; Imipramine; Male | 1979 |
Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels.
Topics: Age Factors; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Desipramine; Drug Interact | 1979 |
Clinical utility of tricyclic antidepressant blood levels: a case report.
Topics: Aged; Aging; Depression; Desipramine; Drug Therapy, Combination; Female; Humans; Imipramine; Phenoth | 1979 |
The kinetics of imipramine-N-oxide in man.
Topics: Administration, Oral; Adult; Biological Availability; Depression; Desipramine; Drug Evaluation; Fema | 1978 |
Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature -- part II.
Topics: Antidepressive Agents, Tricyclic; Biotransformation; Clomipramine; Depression; Desipramine; Dibenzoc | 1979 |
The electroencephalographic and psychological effects of imipramine in depressed inpatients.
Topics: Adult; Depression; Desipramine; Electroencephalography; Female; Humans; Imipramine; Male; Middle Age | 1977 |
Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time.
Topics: Adult; Blood Specimen Collection; Depression; Desipramine; Drug Administration Schedule; Female; Hal | 1978 |
Studies on plasma level/effect relationships in imipramine therapy.
Topics: Depression; Desipramine; Humans; Imipramine; Kinetics; Methods | 1978 |
Clinical implications of imipramine plasma levels for depressive illness.
Topics: Bipolar Disorder; Delusions; Depression; Desipramine; Dose-Response Relationship, Drug; Female; Huma | 1977 |
Relationship between age and tricyclic antidepressant plasma levels.
Topics: Administration, Oral; Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Bod | 1977 |
Tricyclic antidepressants, tryptophan and affective disorder.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Depression; Desipramine; Humans; Serotonin; Tryptoph | 1976 |
Correlation between plasma and cerebrospinal levels of imipramine.
Topics: Depression; Desipramine; Humans; Imipramine | 1976 |
[Psychotropic drugs and glaucoma (author's transl)].
Topics: Adult; Aged; Clomipramine; Depression; Desipramine; Dibenzocycloheptenes; Female; Fluphenazine; Glau | 1976 |
Plasma levels of imipramine in depression. Environmental and genetic factors.
Topics: Adult; Binding Sites; Biological Availability; Depression; Desipramine; Humans; Hydroxylation; Imipr | 1976 |
Patterns of symptom change in anxious depressed outpatients treated with different drugs.
Topics: Amitriptyline; Antidepressive Agents; Anxiety; Chlordiazepoxide; Chlorpromazine; Depression; Desipra | 1975 |
Gas chromatographic-mass fragmentographic determation of "steady-state" plasma levels of imipramine and desipramine in chronically treated patients.
Topics: Chromatography, Gas; Depression; Desipramine; Dose-Response Relationship, Drug; Female; Gas Chromato | 1975 |
Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression.
Topics: Amitriptyline; Biogenic Amines; Depression; Desipramine; Dextroamphetamine; Humans; Hydroxyindoleace | 1975 |
Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Buspirone; Depression; Desipramine; | 1992 |
Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression.
Topics: Actins; Animals; Brain; Depression; Desipramine; Disease Models, Animal; Endocrine Glands; Gene Expr | 1992 |
Depression in elderly is common but undertreated, says expert panel.
Topics: Age Factors; Aged; Antidepressive Agents; Depression; Desipramine; Humans; Nortriptyline | 1992 |
Immobility-reducing effects of antidepressants in a genetic animal model of depression.
Topics: Animals; Antidepressive Agents; Depression; Depression, Chemical; Desipramine; Disease Models, Anima | 1992 |
Alpha 2-adrenoceptor blockade prevents the effect of desipramine in the forced swimming test.
Topics: Adrenergic alpha-Antagonists; Animals; Buspirone; Depression; Desipramine; Dioxanes; Hydroxydopamine | 1990 |
Effects of TRH and prolactin in the behavioral despair (swim) model of depression in rats.
Topics: Aging; Animals; Behavior, Animal; Depression; Desipramine; Injections, Intraventricular; Injections, | 1990 |
The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test.
Topics: Animals; Depression; Desipramine; Dopamine; Fluphenazine; Hydroxydopamines; Injections; Limbic Syste | 1990 |
Imipramine pharmacokinetics in depressed geriatric patients.
Topics: Adult; Age Factors; Aged; Chromatography, High Pressure Liquid; Depression; Desipramine; Female; Hum | 1990 |
Lofepramine, desipramine and abnormal tests of liver function: a case report.
Topics: Depression; Desipramine; Humans; Liver Function Tests; Lofepramine; Male; Middle Aged | 1990 |
Combined effects of desipramine and stress on monoamine turnover in rat brain.
Topics: Animals; Biogenic Monoamines; Brain; Chromatography, High Pressure Liquid; Depression; Desipramine; | 1990 |
1-(3-Trifluoromethylphenyl) piperazine (TFMPP) in the ventral tegmental area reduces the effect of desipramine in the forced swimming test in rats: possible role of serotonin receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Depression; Desipramine; Injections; Male; Metergol | 1989 |
Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression.
Topics: Animals; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Dose-Response Relationsh | 1989 |
[Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants].
Topics: Agonistic Behavior; Animals; Body Temperature; Depression; Desipramine; Disease Models, Animal; Dose | 1989 |
Increased adult behavioral 'despair' in rats neonatally exposed to desipramine or zimeldine: an animal model of depression?
Topics: Animals; Animals, Newborn; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Male; | 1987 |
Role of central histaminergic mechanism in behavioural depression (swimming despair) in mice.
Topics: Animals; Atropine; Central Nervous System; Cimetidine; Depression; Desipramine; Disease Models, Anim | 1988 |
Neuroendocrine and other studies of the mechanism of antidepressant action of desipramine.
Topics: Animals; Blood Pressure; Clonidine; Depression; Desipramine; Growth Hormone; Humans; Melatonin; Phen | 1986 |
Reduced anti-immobility effect of repeated desipramine (DMI) treatment in adult rats undernourished at perinatal age.
Topics: Animals; Depression; Desipramine; Disease Models, Animal; Drug Administration Schedule; Female; Male | 1987 |
Changes in dopamine autoreceptor sensitivity in an animal model of depression.
Topics: Animals; Apomorphine; Body Weight; Depression; Desipramine; Disease Models, Animal; Eating; Male; Ra | 1988 |
[A case of dynamic ileus caused by tricyclic antidepressive agents].
Topics: Antidepressive Agents, Tricyclic; Depression; Desipramine; Drug Therapy, Combination; Female; Humans | 1988 |
Effectiveness of desipramine in the treatment of dyshidrosis.
Topics: Adult; Depression; Desipramine; Hand Dermatoses; Humans; Male | 1988 |
Desipramine for interstitial cystitis.
Topics: Adult; Cystitis; Depression; Desipramine; Female; Humans; Mandelic Acids | 1988 |
Patterns of melatonin rhythms in depression.
Topics: Adult; Circadian Rhythm; Depression; Depressive Disorder; Desipramine; Female; Humans; Isoproterenol | 1986 |
Targeting imipramine dose in children with depression.
Topics: Absorption; Administration, Oral; Child; Depression; Desipramine; Female; Half-Life; Humans; Imipram | 1986 |
Profound behavioral toxicity due to tricyclic antidepressants.
Topics: Acute Disease; Adult; Age Factors; Depression; Desipramine; Female; Hospitalization; Humans; Imipram | 1986 |
Cardiovascular effects of polycyclic antidepressants.
Topics: Adult; Amitriptyline; Amoxapine; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Depression; | 1986 |
Blockade of a 5-hydroxytryptophan-induced animal model of depression with a potent and selective 5-HT2 receptor antagonist (LY53857).
Topics: 5-Hydroxytryptophan; Animals; Cerebral Cortex; Conditioning, Operant; Depression; Desipramine; Disea | 1985 |
Tricyclic antidepressant and metabolite levels in chronic renal failure.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Chromatography, Liquid; Depression; Desipramine; | 1985 |
Lithium as an adjunct treatment in obsessive-compulsive disorder.
Topics: Adult; Depression; Desipramine; Drug Therapy, Combination; Humans; Lithium; Male; Obsessive-Compulsi | 1985 |
Withdrawal symptoms in neonates associated with maternal antidepressant therapy.
Topics: Adult; Depression; Desipramine; Female; Fetus; Humans; Infant, Newborn; Infant, Newborn, Diseases; M | 1973 |
Stages of schizophrenic decompensation and reintegration.
Topics: Adult; Affect; Aggression; Antipsychotic Agents; Anxiety; Depression; Desipramine; Fear; Female; Flu | 1973 |
Theoretical implications of drug-induced adaptive regulation for a biogenic amine hypothesis of affective disorder.
Topics: Animals; Biogenic Amines; Brain Chemistry; Catecholamines; Caudate Nucleus; Cerebral Cortex; Depress | 1974 |
Effect of antidepressant drugs on sleeping and dreaming. 3. On the depressed patient.
Topics: Adult; Antidepressive Agents; Depression; Desipramine; Dreams; Electroencephalography; Electrooculog | 1969 |
Sleep and depression. IV. Longitudinal studies.
Topics: Adult; Depression; Desipramine; Electroconvulsive Therapy; Ethynodiol Diacetate; Female; Hospitaliza | 1971 |
On the treatment of rapid eye movement narcolepsy.
Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Depression; Desipramine; Electroencephalograph | 1974 |
Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Brain; Central Nervous System Stimulants; Chlorpro | 1967 |
The effects of hypnotics on imipramine treatment.
Topics: Adult; Amobarbital; Depression; Desipramine; Drug Interactions; Drug Therapy, Combination; Female; H | 1974 |
Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states.
Topics: Adjustment Disorders; Adult; Amitriptyline; Antidepressive Agents; Anxiety; Bipolar Disorder; Blood | 1974 |
Quantitative determination of imipramine and desmethylimipramine in human plasma by mass fragmentography.
Topics: Chromatography, Gas; Depression; Desipramine; Humans; Imipramine; Mass Spectrometry | 1974 |
Mind and body in biological psychiatry.
Topics: Adult; Affect; Carbon Dioxide; Chlorpromazine; Conditioning, Classical; Depression; Desipramine; Ere | 1973 |
[Combination of L-dopa, desipramine, and a decarboxylase inhibitor in the treatment of depression (author's transl)].
Topics: Adult; Aged; Anxiety; Carbidopa; Carboxy-Lyases; Depression; Desipramine; Dihydroxyphenylalanine; Dr | 1973 |
Biological and pharmacokinetic evidence for generic equivalence of three imipramine preparations: comparison with a new imipramine analogue.
Topics: Animals; Depression; Desipramine; Humans; Imipramine; Iris; Norepinephrine; Solubility; Tablets; The | 1973 |
Treatment of the depressed outpatient.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety; Child; Chlordiazepoxide; Dep | 1974 |
A potential clinical use for methylphenidate with tricyclic antidepressants.
Topics: Adult; Aged; Animals; Chloral Hydrate; Chromatography, Thin Layer; Depression; Desipramine; Dextroam | 1971 |
Urinary elimination of phenethylamine.
Topics: Chromatography, Gas; Depression; Desipramine; Dibenzazepines; Epilepsy, Temporal Lobe; Humans; Menta | 1972 |
A brief rating scale for antidepressant drug trials.
Topics: Alcoholism; Antidepressive Agents; Depression; Desipramine; Humans | 1971 |
Possible involvement of glycogen phosphorylase of brain in the affective states.
Topics: Amphetamine; Animals; Antidepressive Agents; Brain; Chlorpromazine; Depression; Desipramine; Drug In | 1971 |
[Differential therapeutic experiments with antidepressive efficacious psychopharmacotics].
Topics: Amitriptyline; Antidepressive Agents; Depression; Desipramine; Humans; Imipramine; Psychopharmacolog | 1967 |
[Desipramine in the treatment of depressions in ambulatory care and hospital care].
Topics: Bipolar Disorder; Depression; Desipramine; Humans | 1966 |
[Treatment of depressive states with desipramine].
Topics: Depression; Desipramine; Humans | 1967 |
[Effect of thymoleptics on acid production of the stomach. Preliminary report].
Topics: Amitriptyline; Chlorpromazine; Depression; Depression, Chemical; Desipramine; Dibenzazepines; Gastri | 1969 |
[Current problems of endogenous depression].
Topics: Amitriptyline; Antidepressive Agents; Chlorpromazine; Convulsive Therapy; Depression; Desipramine; F | 1970 |
[Clinical antidepressant drug therapy].
Topics: Amitriptyline; Antidepressive Agents; Depression; Desipramine; Dibenzazepines; Humans; Imipramine; N | 1970 |
Delayed absorption of phenylbutazone caused by desmethylimipramine in humans.
Topics: Depression; Desipramine; Female; Humans; Male; Phenylbutazone; Time Factors | 1970 |
[Parenteral treatment of depressive diseases].
Topics: Antidepressive Agents; Bipolar Disorder; Dementia; Depression; Depressive Disorder, Major; Desiprami | 1970 |
Antianxiety and anti-depressant drugs.
Topics: Amitriptyline; Antidepressive Agents; Anxiety; Chlordiazepoxide; Depression; Desipramine; Dibenzoxep | 1970 |
[Psychosensory phenomena during treatment with tricyclic thymoanaleptics (presentation of 2 cases)].
Topics: Depression; Desipramine; Female; Hallucinations; Humans; Imipramine; Male; Middle Aged; Tranquilizin | 1970 |
[Intragastric telemetric pH measuring during thymoleptic therapy].
Topics: Amitriptyline; Depression; Depression, Chemical; Desipramine; Dibenzazepines; Female; Gastric Acidit | 1970 |
Tricyclic antidepressants and monoamine oxidase inhibitors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amitriptyline; Animals; Depression; Desipramine; Drug | 1971 |
[Desipramine (Sertofren) in the treatment of depression].
Topics: Aged; Asthenia; Depression; Desipramine; Electroconvulsive Therapy; Female; Humans; Middle Aged; Tac | 1967 |
[Comparative clinical-experimental studies on imipramine and desipramine].
Topics: Blood Circulation; Blood Pressure; Depression; Desipramine; Drug Synergism; Heart; Humans; Imipramin | 1967 |
[Cardiac complications in poisoning with desipramine (Pertofran)].
Topics: Adult; Arrhythmias, Cardiac; Depression; Desipramine; Electrocardiography; Female; Humans; Suicide | 1967 |
[Comparative clinical experiences with dibenzazepine and dibenzodiazepine derivatives].
Topics: Antidepressive Agents; Depression; Desipramine; Dibenzazepines; Humans; Imipramine; Middle Aged; Sch | 1967 |
[Trial of G. 35020 in 52 cases of depression].
Topics: Adult; Aged; Bipolar Disorder; Depression; Depressive Disorder, Major; Desipramine; Female; Humans; | 1968 |
[Apropos of 60 patients treated with Pertofran].
Topics: Adult; Depression; Desipramine; Female; Humans; Male; Middle Aged; Schizophrenia | 1968 |
[The use of desipramine (DMI) by slow intravenous infusion in the treatment of depression].
Topics: Adult; Depression; Desipramine; Dibenzazepines; Electroconvulsive Therapy; Humans; Injections, Intra | 1968 |
[Clinical trial of a new thymoanaleptic: desmethylimipramine or pertofran].
Topics: Adolescent; Adult; Aged; Depression; Desipramine; Female; Humans; Middle Aged | 1968 |
[Response to psychotropic drugs in depressive syndromes. Clinico-statistical contribution].
Topics: Antidepressive Agents; Depression; Desipramine; Humans; Imipramine; Monoamine Oxidase Inhibitors | 1968 |
Clinical significance of anticholinergic effects of imipramine-like drugs.
Topics: Amitriptyline; Animals; Atropine; Columbidae; Depression; Desipramine; Diphenhydramine; Humans; Imip | 1969 |
Desipramine.
Topics: Amitriptyline; Depression; Desipramine; Humans; Nortriptyline | 1965 |
[Clinical experience with desmethylimipramine in depressive patients].
Topics: Depression; Desipramine; Humans | 1965 |
Depression: treatment with desipramine.
Topics: Adolescent; Adult; Aged; Depression; Desipramine; Female; Humans; Male; Middle Aged | 1965 |
Desipramine and imipramine in an outpatient setting: a comparative study.
Topics: Adolescent; Adult; Depression; Desipramine; Humans; Imipramine; Middle Aged | 1965 |
[Contribution to the study of the therapeutic spectrum of desmethylimipramine].
Topics: Depression; Desipramine; Humans | 1965 |
Preliminary report on nor-imipramine treatment of depressions.
Topics: Depression; Desipramine; Electroencephalography; Female; Humans; Male; Middle Aged | 1965 |
Nocturnal enuresis: remission in a patient treated with desipramine and protriptyline.
Topics: Adult; Antidepressive Agents; Depression; Desipramine; Enuresis; Female; Humans | 1966 |
[Clinical trials of an antidepressant: G 35020].
Topics: Adult; Aged; Depression; Desipramine; Female; Humans; Male; Middle Aged | 1966 |
Diagnosis and treatment of depressive reactions.
Topics: Antidepressive Agents; Depression; Desipramine; Humans; Nortriptyline | 1966 |
[Observations and clinical results in the treatment of depressions with G 35020].
Topics: Depression; Desipramine; Humans | 1966 |
[Clinical experience with desipramine in depressive states].
Topics: Adult; Depression; Desipramine; Dissociative Disorders; Female; Humans; Male | 1966 |